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A B S T R A C T
Background
Seasonal/perennial allergic conjunctivitis is the most common allergic conjunctivitis, usually with acute manifestations when a person
is exposed to allergens and with typical signs and symptoms including itching, redness, and tearing. The clinical signs and symptoms of
allergic conjunctivitis are mediated by the release of histamine by mast cells. Histamine antagonists (also called antihistamines) inhibit
the action of histamine by blocking histamine H1 receptors, antagonising the vasoconstrictor, and to a lesser extent, the vasodilator
effects of histamine. Mast cell stabilisers inhibit degranulation and consequently the release of histamine by interrupting the normal
chain of intracellular signals.
Topical treatments include eye drops with antihistamines, mast cell stabilisers, non-steroidal anti-inflammatory drugs, combinations of
the previous treatments, and corticosteroids. Standard treatment is based on topical antihistamines alone or topical mast cell stabilisers
alone or a combination of treatments. There is clinical uncertainty about the relative efficacy and safety of topical treatment.
Objectives
The objective of this review was to assess the effects of topical antihistamines and mast cell stabilisers, alone or in combination, for use
in treating seasonal and perennial allergic conjunctivitis.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2014, Issue 7), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to July
2014), EMBASE (January 1980 to July 2014), themetaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 17 July 2014. We also searched the reference lists of review articles and relevant trial reports for details of
further relevant publications.
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Selection criteria
We included randomised controlled trials (RCTs) comparing topical antihistamine and mast cell stabilisers, alone or in combination,
with placebo, no treatment or to any other antihistamine or mast cell stabiliser, or both, that examined people with seasonal or perennial
allergic conjunctivitis, or both. The primary outcome was any participant-reported evaluation (by questionnaire) of severity of four
main ocular symptoms: itching, irritation, watering eye (tearing), and photophobia (dislike of light), both separately and, if possible,
by an overall symptom score. We considered any follow-up time between one week and one year.
Data collection and analysis
Two review authors independently extracted data and assessed risk of bias. Disagreements were resolved by discussion among review
authors and the involvement of a third review author. We followed standard methodological approaches used by Cochrane.
Main results
We identified 30 trials with a total of 4344 participants randomised, with 17 different drugs or treatment comparisons. The following
antihistamines and mast cell stabilisers were evaluated in at least one RCT: nedocromil sodium or sodium cromoglycate, olopatadine,
ketotifen, azelastine, emedastine, levocabastine (or levocabastine), mequitazine, bepotastine besilate, combination of antazoline and
tetryzoline, combination of levocabastine and pemirolast potassium. The most common comparison was azelastine versus placebo (nine
studies).
We observed a large variability in reporting outcomes. The quality of the studies and reporting was variable, but overall the risk of bias
was low. Trials evaluated only short-term effects, with a range of treatment of one to eight weeks. Meta-analysis was only possible in
one comparison (olopatadine versus ketotifen). There was some evidence to support that topical antihistamines and mast cell stabilisers
reduce symptoms and signs of seasonal allergic conjunctivitis when compared with placebo. There were no reported serious adverse
events related to the use of topical antihistamine and mast cell stabilisers treatment.
Authors’ conclusions
It seems that all reported topical antihistamines and mast cell stabilisers reduce symptoms and signs of seasonal allergic conjunctivitis
when compared with placebo in the short term. However, there is no long-term data on their efficacy. Direct comparisons of different
antihistamines and mast cell stabilisers need to be interpreted with caution. Overall, topical antihistamines and mast cell stabilisers
appear to be safe and well tolerated. We observed a large variability in outcomes reported. Poor quality of reporting challenged the
synthesis of evidence.
P L A I N L A N G U A G E S U M M A R Y
Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis
Review question
Are treatments with eye drops of antihistamines and mast cell stabilisers, alone or in combination, effective and safe in people with
seasonal and allergic conjunctivitis? The main outcome measure was eye symptoms reported by participants, including eye itching,
irritation (burning sensation), watering eyes (tearing), and photophobia (dislike of light). We found 30 trials.
Background
Conjunctivitis refers to inflammation of the conjunctiva, which is the thin tissue that covers the sclera (white part of the eye). Seasonal
and perennial allergic conjunctivitis is the most common type of allergic conjunctivitis. Although this condition does not cause sight
loss, it can cause intense itching and eye watering. Eye drops with antihistamines or mast cell stabilisers, or both are commonly used.
Study characteristics
The evidence is current to July 2014. Among the 30 studies reviewed there were 17 different comparisons, including 4344 participants
ranging in age between 4 and 85 years. The duration of treatment ranged from one to eight weeks. Ten out of 30 studies were funded
by the drug manufacturer (8 totally and 2 partially funded); 20 studies did not report any source of funding. There was inconsistency
in the way the effect of treatment was measured and reported. Overall risk of bias was low.
Key results
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Topical antihistamines and mast cell stabilisers, alone or in combination, are safe and effective for reducing symptoms of seasonal and
perennial allergic conjunctivitis. We found insufficient evidence to discern which topical antihistamines and mast cell stabilisers are the
most effective.
B A C K G R O U N D
Description of the condition
The conjunctiva forms the mucous membrane component of the
ocular surface and is continually exposed to a wide variety of al-
lergens. In sensitised individuals, pollen, plant, house dust mite
or animal dander allergens dissolve in the tear film, cross the con-
junctival epithelium, and activate mast cells in the substantia pro-
pria leading to the prevalent and unpleasant conditions known as
seasonal allergic conjunctivitis (SAC) and perennial allergic con-
junctivitis (PAC) (Anderson 2001).
SAC is the most common allergic conjunctivitis, usually with an
acute or subacute manifestation characterised by peaks of self lim-
iting signs and symptoms that become persistent in repeated al-
lergen stimulations during the pollen season. The hallmark signs
and symptoms are itching, redness, and lid swelling. Patients may
also complain of epiphora (watering eye), mucous (translucent)
discharge, rhinitis (runny or stuffy nose), and eye-burning sensa-
tion (Leonardi 2008).
In PAC, the non-specific signs and symptoms of redness, burn-
ing, and chemosis (swelling of the conjunctiva) may persist with
varying severity for months, accompanied by a low level of itching
(Leonardi 2008).
Seasonal and perennial allergic conjunctivitis rarely cause visual
disability.
Epidemiology
SAC is the most common allergic eye disorder, affecting up to
20% of the population in the United Kingdom at some point in
their lives (Buckley 1998; Dart 1986). It has a varying prevalence
in countries throughout the world (Beasley 1998). PAC is much
rarer and typically results in milder symptoms than those seen in
the seasonal condition. People with allergic conjunctivitis often
have a personal history, family history, or both of atopic disorders.
A recent epidemiological survey noted that up to 40% of 13 and
14-year-olds worldwide reported the symptoms of allergic con-
junctivitis (see ’Clinical presentation’ below) (Strachan 1997). It
has been estimated that ocular symptoms are present in 40% to
60% of the allergic population (people with atopy, that is asthma
and eczema) (Ono 2005). Visual loss and severe complications are
rare.
Biological mechanism
Allergic conjunctivitis results from a Type 1 (immediate) im-
munoglobulin E (IgE)-mediated hypersensitivity reaction. The al-
lergen particles bind to and cross-link IgE molecules that are at-
tached to tissue mast cells, resulting in mast cell degranulation and
release of histamines and other inflammatory mediators into the
tissue. Histamine is the primary contributor to the development of
early-phase signs and symptoms of SAC (Abelson 1979). A com-
prehensive summary of these is provided in Hingorani 1997.
Clinical presentation
Allergic conjunctivitis is usually bilateral. The main defining fea-
ture of this type of conjunctivitis is intense itching.More than 75%
of patients report this symptomwhen seeking treatment (Whitcup
2006). Other signs and symptoms include epiphora, hyperaemia
(engorgement of blood vessels of the conjunctiva), micropapil-
lae (little bumps on the inner surface of the eyelid), conjuncti-
val chemosis (swelling of the conjunctiva), and thin mucous dis-
charge.
If accompanied by rhinitis (sneezing, rhinorrhoea (runny nose),
nasal itch or blockage), the symptom complex is sometimes re-
ferred to as rhinoconjunctivitis. Coughing and wheezing due to
asthma may also co-exist. Diagnosis is usually on the basis of a
careful allergy history and examination of the conjunctiva. Skin-
prick tests, serum-specific IgE, and conjunctival allergen challenge
may be used to confirm the allergic trigger.
Description of the intervention
A variety of drugs have been used to treat allergic conjunctivitis,
which can be administered orally or applied directly to the eye.
Systemic treatment with oral antihistamines is usually indicated
when other symptoms are being treated along with the conjunc-
tivitis, such as rhinitis. Topical treatments include antihistamines,
mast cell stabilisers, non-steroidal anti-inflammatory drugs, and
corticosteroids, the last being reserved for severe symptoms that
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are unresponsive to other treatments and given for a short period
of time.
How the intervention might work
The pharmacological effects of antihistamines are based on their
abilities to block histamine H1 receptors. H1 receptors are acti-
vated by histamine, which has many actions. Histamine mediates
the tissue response to injury (for example mechanical, thermal,
infections, etc.). It is also a mediator of gastric acid secretion and
may serve as a neurotransmitter. With respect to conjunctivitis,
the action of antihistamines is to antagonise the vasoconstrictor,
and, to a lesser extent, the vasodilator effects of histamine. Some
antihistamines have central effects like sedation, which can influ-
ence their use when administered systemically.
Mast cell stabilisers inhibit degranulation by interrupting the nor-
mal chain of intracellular signals resulting from the cross-linking
and activation of FceRI by allergen (Cook 2002). They inhibit
mast cell degranulation, the release of histamine, and the other
preformed mediators and the arachidonic acid cascade (Leonardi
2005).
Why it is important to do this review
As allergic conjunctivitis is considered to be a leading cause of
acute red eye presentation to hospital, optometrists, and general
practitioners, it has a significant impact on health service provi-
sion. The spectrum of disease varies from mild to severe and can
therefore interfere with quality of life. It also has the potential to
compromise visual function, although this is rarely seen.
Standard treatment is topical antihistamines alone or in combina-
tion with topical mast cell stabilisers. There is clinical uncertainty
about the relative efficacy of this treatment.
O B J E C T I V E S
The objective of this review was to assess the effects of topical
antihistamines and mast cell stabilisers, alone or in combination,
for use in treating seasonal and perennial allergic conjunctivitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only.
We excluded within-person trials (in which eyes were randomly
allocated to different treatments).
Types of participants
We included trials that recruited children or adults with seasonal
allergic conjunctivitis (SAC) or perennial allergic conjunctivitis
(PAC). This review did not cover other allergic conjunctivitis en-
tities such as vernal keratoconjunctivitis, atopic keratoconjunc-
tivitis, and giant papillary conjunctivitis. We attempted to obtain
separate data for participants with SAC or PAC where trials also
included participants with other types of conjunctivitis.
The diagnosis was done clinically based on the presence of typical
symptoms and signs.
We excluded trials conducted with the use of conjunctival aller-
gen challenge or conjunctival provocation testing, as it would be
difficult to compare the data with trials that have participants who
were recruited with active symptomatic disease without provoca-
tion tests. In addition, information from trials using provocation
or challenge might not be representative and generalisable of the
condition observed in routine practice.
We excluded people with allergic eye disease associated with atopy.
Types of interventions
This review included trials comparing topical antihistamines and
mast cell stabilisers, alone or in combination, with placebo, no
treatment, or any other antihistamine and/or mast cell stabiliser.
These included the medications listed in Appendix 1 and any
other pure antihistamine alone or in combination with a mast cell
stabiliser not originally listed.
We placed no restriction on the duration of treatment in the trials.
We did not include any trials that used herbal, oral, nasal antihis-
tamines and any other medication.
Types of outcome measures
Primary outcomes
The primary outcome was any participant-reported evaluation (by
questionnaire) of severity of four main ocular symptoms: itching,
irritation, watering eye, and photophobia (dislike of light), both
separately and, if possible, by an overall symptom score. We con-
sidered any follow-up time between one week and one year.
As there are a variety of different questionnaires evaluating ocular
symptoms, we tried to transform data to common measurements
where possible to facilitate meta-analysis using the standardised
mean difference. We used this only if studies utilised different
participant-reported outcomes measuring a comparable range of
symptoms.
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Secondary outcomes
Secondary outcomes were measured at any reported follow-up
time and included:
• Adverse events.
• Signs of hyperaemia and redness, chemosis, tarsal papillae
(little bumps on inner surface of eyelid). Signs were clinician/
investigator assessed and analysed using categorisation where
appropriate.
• Duration of symptoms (days) of acute episodes.
• Incidence of acute episodes (per year).
A variety of numeric rating scales were used to assess participant-
and clinician-reported symptoms in the included studies. Unless
stated otherwise, higher scores represent higher levels of symptoms
than lower scores.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes and
Vision Trials Register) (2014, Issue 7), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid
MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to July
2014), EMBASE (January 1980 to July 2014), the metaRegister
of Controlled Trials (mRCT) (www.controlled-trials.com), Clini-
calTrials.gov (www.clinicaltrials.gov) and theWorld Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 17 July 2014.
See: Appendices for details of search strategies for CENTRAL
(Appendix 2),MEDLINE (Appendix 3), EMBASE (Appendix 4),
mRCT (Appendix 5), ClinicalTrials.gov (Appendix 6), and the
ICTRP (Appendix 7).
Searching other resources
We searched the reference lists of review articles, book chapters,
and relevant trial reports for details of further relevant publica-
tions. We planned to contact authors for data queries. We used
the Science Citation Index to search for references that cite the
studies that were included in the review.
Data collection and analysis
Selection of studies
Two review authors (MSM, MC/MZM) independently assessed
the titles and abstracts resulting from the manual and electronic
searches for selection of studies for inclusion. We obtained full
copies of all relevant or potentially relevant trials and assessed these
according to the ’Criteria for considering studies for this review’
section. The investigators were not masked to the names of au-
thors, institutions, journal of publication, or results when they
made their assessments. We resolved disagreements about whether
a trial should be included by discussion with a third review author
(AAB) and consensus. In cases where we needed additional infor-
mation before we could make a decision about whether or not to
include a trial, we planned to obtain this information by contact-
ing the trial authors when author contact details were available.
We attempted to obtain further information about any trial that
had been published only as an abstract by contacting authors if
contact details were available. If a full report was not available, we
planned to assess and include data from abstracts for the review
and meta-analysis. If there was not sufficient abstract data for the
meta-analysis, we still planned to present the abstract data in the
review to ensure no significant information was lost.
Using a form developed to document the process, we divided the
full copies into two groups: 1) definitely include and 2) definitely
exclude.
Agreement between the two review authors was recorded. At this
stage, we excluded only those papers that both review authors had
assigned to the ’definitely exclude’ group. We documented and
reported these exclusions in the review.We assessed all other papers
for methodological quality.
Data extraction and management
As well as recording information about the methods used in the
trial, we extracted the following information from the trial reports
using a standardised form:
• details of participants (age, gender, setting, number in each
group, comparability at baseline);
• details of interventions (dosage, schedule, compliance,
comparison group, timing);
• outcomes (primary and secondary outcomes, adverse
effects);
• other information (source of funding, declaration of
interest).
Two review authors (MSM, MC/MZM) independently extracted
the data for the primary and secondary outcomes on to a standard-
ised form. One review author (MC) entered data into RevMan
(RevMan 2014), and a second review author (AAB) checked the
data entered into RevMan to ensure that no mistakes had been
made. The review authors resolved any differences by discussion.
If there was any doubt about the data of a trial, the review authors
contacted the authors of the trial. Where studies were reported in
more than one publication, we extracted data from each report
separately. We then collated the information from the multiple
data collection forms.
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Assessment of risk of bias in included studies
Two review authors (MC, AAB) evaluated the risk of bias inde-
pendently. They met after completion to identify disagreements.
Review authors assessed trial quality according to the methods set
out in Chapter 8 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). We used Cochrane’s ’Risk of bias
tool’ and considered six domains: sequence generation (randomi-
sation), allocation concealment, blinding (masking), incomplete
outcome data (completeness of follow-up), selective outcome re-
porting, and free from other bias.
Two review authors (MC, AAB) assessed the risk of bias for each
parameter and judged each parameter as low risk of bias, high
risk of bias, or unclear (uncertain risk of bias where there was
insufficient information to be able to judge).
We planned to perform a sensitivity analysis, if possible, excluding
studies with high risk of bias to determine the effect of this decision
on the results (Higgins 2011b).
Measures of treatment effect
Dichomotous data
For dichotomous data, we calculated odds ratios and their 95%
confidence intervals.
Continuous data
For continuous data presented using a common scale, we calcu-
lated the mean difference and its 95% confidence interval. For
overall symptom scores, we used the standardised mean difference
was used.
Unit of analysis issues
The unit of randomisation was the individual participant (not eye)
due to potential systemic absorption and effect in the fellow eye; we
therefore only included studies that used the participant as the unit
of randomisation. We considered cross-over trials if there was an
adequate washout (48 hours) between the two treatment periods
and if the treatment was compared with a control placebo. H1
antihistamine terminal elimination half-life values range from 2
hours for acrivastine to 27 hours for desloratadine (Simons 2002).
Dealing with missing data
If data were not obtainable we considered the potential impact
of the missing data on the results and highlighted the potential
impact in the ’Discussion’ section of the review.
Assessment of heterogeneity
Before combining studies we planned to assess clinical heterogene-
ity by examination of the study details and statistical heterogeneity
using the Chi2 test and the I2 statistic. Where we were unable to
pool results we planned to provide a descriptive summary.
Assessment of reporting biases
We minimised reporting bias by maximising our search strategy
to include research that had been published in different languages
as well as unpublished research.
If appropriate, we planned to investigate publication bias by look-
ing at a funnel plot of the data.
Data synthesis
When there were sufficient trials available without substantial het-
erogeneity, we combined studies in a meta-analysis using a ran-
dom-effects model. Where this was not possible, we performed a
narrative synthesis. As we evaluated a network of treatments, we
also planned a network meta-analysis, provided suitable data were
available.
Subgroup analysis and investigation of heterogeneity
Not applicable for this review.
Sensitivity analysis
We planned to perform sensitivity analyses, if possible, to assess
how robust the results were to changes in methods such as:
1. excluding studies of lower methodological quality;
2. excluding unpublished studies;
3. excluding studies that assumed that eyes within a
participant are independent.
R E S U L T S
Description of studies
We have described the studies within the context of each compar-
ison (see ’Effects of interventions’ section).
Results of the search
The electronic searches yielded a total of 2764 references (Figure
1). The Trials Search Co-ordinator removed 1030 duplicate
records, screened 1734 records, and removed 630 references that
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were not relevant to the scope of this review. We screened the re-
maining 1104 references and discarded 1054 reports as not rele-
vant. We obtained 50 full-text reports for potential inclusion in
the review and included 30 studies (see ’Characteristics of included
studies’ section) and excluded 17 studies (see ’Characteristics of
excluded studies’ section). Currently three studies are still awaiting
classification: Scandashree 2013 has insufficient details on out-
come measures, and Jia 2012 and Dharmistha 2013 have insuffi-
cient information on methods of allocation. If we are able to ob-
tain further information on these studies, we will assess them in
future updates of this review.
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Figure 1. Results of searching for studies for inclusion in the review
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Included studies
We included 30 trials with 17 different comparisons (see Figure
2, a network diagram showing the number of studies contributing
to each of the 17 comparisons).
Figure 2. Network diagram: Number of studies by treatment comparison
Excluded studies
We excluded 17 studies that did not meet the inclusion criteria
(see ’Characteristics of excluded studies’ section).
Risk of bias in included studies
We summarised risk of bias in Figure 3 and Figure 4. Most studies
had low risk of bias regarding the masking of participants and in-
vestigators and selective reporting. Information on sequence gen-
eration and allocation concealment was frequently missing.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Figure 4. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
Allocation
We judged the method of randomisation to be at low risk of se-
lection bias in approximately 37% of the studies (Figure 3).
Allocation concealment was the item with the lowest proportion
(less than 10%) of studies judged to be at low risk of bias. We
judged more than 90% of studies as at unclear risk of selection
bias on the basis of inadequate or no information provided on the
method of allocation concealment.
Blinding
We judged the majority (approximately 62%) of studies as at low
risk of detection bias (masking of outcome assessment) and con-
sidered a similar proportion as at low risk of performance bias
(masking of participants and investigators) (Figure 3).
Incomplete outcome data
Over 50% of the studies have low risk of bias for this domain.
We judged a lower proportion of studies (approximately 36%)
with unclear risk of bias, as some of the trials did not conduct
an intention-to-treat analysis, or no reasons for dropouts were
described (Figure 3).
Selective reporting
We judged a highest proportion of studies (75%) with low risk of
bias for this domain.
Other potential sources of bias
Not applicable for this review.
Effects of interventions
Drug comparisons
We have used the following order to describe the comparisons:
placebo-controlled studies with mast cell stabilisers (comparison
1); placebo-controlled studies with antihistamines (comparisons
2 and 3, in order of number of studies available); and comparative
studies of antihistamines and/or mast cell stabilisers (comparisons
4 to 16, in order of number of studies available). We described
primary and safety outcomes for each comparison. Secondary out-
comes were either not reported (duration of symptoms of acute
episodes and incididence of acute episodes) or uncommonly re-
ported and using different measures and scales (signs evaluated by
an investigator) and thus were not analysed.
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1. Nedocromil sodium/sodium cromoglycate versus placebo
The search identified eight eligible studies comparing the mast
cell stabilisers nedocromil sodium or sodium cromoglycate against
placebo (Azevedo 1991; Davies 1993; Hechanova 1984; James
2003; Leino 1992;Melamed 1994;Melamed 2000;Möller 1994).
One study was a three-arm trial comparing both nedocromil
sodium and sodium cromoglycate with placebo (Leino 1992). Of
the remaining seven studies, four examined sodium cromoglycate
(Azevedo 1991; Davies 1993; Hechanova 1984; James 2003), and
two examined nedocromil sodium (Melamed 2000;Möller 1994).
Three studies also included a third treatment arm: either levo-
cabastine, in Azevedo 1991 and Davies 1993, or azelastine (James
2003). One study was reported in two publications (Melamed
1994;Melamed 2000); Melamed 2000 reported combined results
from two separate studies, one of which had been previously re-
ported in Melamed 1994.
The number of participants randomised (or analysed if numbers
randomised not known) to nedocromil sodium/sodium cromo-
glycate and placebo were 21 versus 21 (Azevedo 1991), 32 versus
32 (Davies 1993), 20 versus 20 (Hechanova 1984), 50 versus 49
(James 2003), 61 versus 64 (Leino 1992), 43 versus 43 (Melamed
1994), 94 versus 95 (Melamed 2000), and 77 versus 72 (Möller
1994), respectively.
Duration of treatment was two weeks in one study (James 2003),
four weeks in five studies, and eight weeks in one study (Melamed
1994; Melamed 2000).
Primary outcomes
Although all eight studies reported at least one of the four symp-
toms prespecified as primary outcomes (itching, irritation, water-
ing eyes, or photophobia), there was considerable variation in how
these outcomes were reported (Table 1).
Six studies collected data on itching. Three of these studies col-
lected participant-reported itching scores using a 0-4 scale, how-
ever as no studies also reported a standard deviation, we considered
it not possible to perform formal meta-analysis. All studies did
report less itching for the active treatment group compared with
placebo. Hechanova 1984 presented mean participant-reported
scores of 0.96 (sodium cromoglycate) versus 2.10 (placebo) at 14
days, with even larger differences in favour of the active treatment
at 21 and 28 days. Melamed 1994 reported scores (it was un-
clear whether this was the mean or median) of 1.14 (nedocromil
sodium) versus 1.48 (placebo) at 14 days. Melamed 2000 reported
only change scores from baseline to the peak pollen period and
found a statistically significant difference in favour of nedocromil
sodium. Möller 1994 reported mean scores of 0.9 (nedocromil
sodium) versus 1.4 (placebo) during peak pollen challenge in a
graph. Leino 1992 reported that both the sodium cromoglycate
and nedocromil sodium groups had statistically significantly less
itching than the placebo group, but presented no data. James 2003
only reported itching as part of an overall symptom score plus
the proportion of participants with improvement in itching in
each group between days 0 and 3. AlthoughDavies 1993 collected
daily data on itch from participant diaries, this publication did
not specifically report any data.
Three studies presented data for participant-reported ocular irri-
tation (including grittiness and foreign body sensation), but over-
all the evidence for the effectiveness of the active treatment was
limited. At 14 days, Hechanova 1984 reported mean grittiness
scores of 0.58 (sodium cromoglycate) versus 1.31 (placebo) using
a 0-4 scale, a difference that was considered statistically signifi-
cant. Azevedo 1991 presented daily mean irritation using a 0-4
scale in a graph: at 14 days, mean irritation was around 1 for both
groups. Between-group differences for the median area under the
curve were also similar when the entire 28-day follow-up period
was considered. In the study by Möller 1994, mean grittiness (es-
timated from a graph) during peak pollen challenge was 0.2 (ne-
docromil sodium) versus 0.5 (placebo). Leino 1992 reported sta-
tistically significant differences in favour of both treatment groups
versus placebo when considering the change from baseline to four
weeks, but not at one week; once again, no actual data were pre-
sented. James 2003 only reported foreign body sensation in terms
of improvement from day 0 to day 3. Davies 1993 also collected
information on ocular irritation, but again did not report this in-
formation directly.
Data on watering eyes was not commonly reported. Using a 0-4
scale,Melamed 1994 reported scores of 0.71 (nedocromil sodium)
versus 1.08 (placebo) at 14 days, but it was unclear whether these
weremean values. In the later publication by this group (Melamed
2000), both treatment groups in fact experienced an increase in
tearing during the peak pollen period. Using a 0-4 scale, Möller
1994 reported mean watering scores of 0.4 (nedocromil sodium)
versus 0.7 (placebo) during peak pollen challenge. Azevedo 1991
only reported changes in tearing over 28 days, and again James
2003 reported improvement in tearing from baseline to day 3.
Davies 1993 and Leino 1992 did not report any information re-
lating to this outcome, even though this had been collected using
participant diaries.
Six studies were known to have collected data on photophobia,
but there was no clear evidence available concerning this out-
come. Two studies did not report any information on this out-
come (Davies 1993; Leino 1992), and two studies reported change
scores (Azevedo 1991; James 2003). Hechanova 1984 reported a
statistically significant difference in favour of sodium cromogly-
cate, but only at the 14-day time point. The remaining study re-
ported mean scores of around 0.3 on a 0-4 scale for both the ne-
docromil sodium and placebo groups (Möller 1994).
Overall symptom score
Five articles representing four studies reported some kind of global
evaluation or overall symptom score (Table 1). Melamed 2000
reported a participant-reported composite symptom score during
12Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the peak pollen period, and similar separate results for one of the
two constituent substudies were also reported (Melamed 1994).
James 2003 reported both investigator- and participant-reported
composite symptom scores up to 14 days. Leino 1992 collected
similar composite scores from investigators and participants but
only reported that there were no statistically significant differences.
Davies 1993 reported the participants’ global evaluation of treat-
ment efficacy using a 4-point scale. Although all available results
from these studies tended to favour the active treatment, no stan-
dard deviations were reported and no formal meta-analysis was
conducted.
Safety
No serious adverse events were observed. Overall, placebo, ne-
docromil sodium, and sodium cromoglycate were well tolerated.
Summary
There was some evidence from individual trials that nedocromil
sodium or sodium cromoglycate is more effective than placebo
in improving ocular symptoms. However, it was not possible to
perform formal meta-analyses for this comparison due to varia-
tion in how outcomes were reported and the lack of suitable data
(especially standard deviations (SDs)).
Table 1. Nedocromil sodium or sodium cromoglycate versus
placebo. Outcome definition, time points, and summary of
results
Article Outcome definition Time point Nedocromil
sodium or sodium
cromoglycate










































graph (no SD). Days









28 days Cromoglycate and
nedocromil:
No data presented
No data presented n = 195
No significant dif-
ferences between the








Mean 5.1 n = 86
No SD. Estimated
from graph in Fig-
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2. Azelastine versus placebo
The search strategy identified nine eligible studies comparing
the antihistamine azelastine against placebo (Canonica 2003;
Giede-Tuch 1998; James 2003; Lenhard 1997; Nazarov 2003;
Petzold 2002; Sabbah 1998). Petzold 2002 summarised data from
three different RCTs, which we analysed as individual studies.
Three studies reported a third treatment arm, comparing azelastine
against levocabastine, in Canonica 2003 and Sabbah 1998, and
azelastine against sodium cromoglycate (James 2003). All studies
were available as full- text papers, except for Petzold 2002, which
was available only as an abstract. Drug concentration was the
same in all studies (azelastine 0.05%), however two studies com-
pared twodifferent concentrations (azelastine 0.05%and0.025%)
(Giede-Tuch 1998; Lenhard 1997). Azelastine was administered
twice a day.
The number of participants randomised (or analysed if numbers
randomised not known) to azelastine and placebo were 57 ver-
sus 56 (Canonica 2003), 99 versus 52 (Giede-Tuch 1998), 45
versus 49 (James 2003), 92 versus 94 (Lenhard 1997), 58 versus
58 (Nazarov 2003), 160 versus 80 (Petzold 2002), 99 versus 46
(Petzold 2002), 49 versus 29 (Petzold 2002), and 51 versus 30
(Sabbah 1998), respectively
Duration of treatment was six weeks in three studies (Canonica
2003; Nazarov 2003; Sabbah 1998), two or four weeks in three
trials reported by Petzold 2002, and two weeks in three other
studies (Giede-Tuch 1998; James 2003; Lenhard 1997).
Primary outcomes
Although all nine studies reported at least one of the four pre-
specified primary outcomes (itching, irritation, watering eyes, or
photophobia), there were some variations in how these outcomes
were reported across the included studies.
Data on itching were collected as mean scores in five studies
using a 0-3 scale, where higher scores represented worse itch-
ing, but as SD was not reported, meta-analysis was not feasible
(Giede-Tuch 1998; James 2003; Lenhard 1997; Nazarov 2003;
Sabbah 1998). All studies reported less itchingwith azelastine com-
pared to placebo, but in some studies it was not possible to confirm
whether the results were statistically significant (Lenhard 1997).
Giede-Tuch 1998 presented participant-reported mean scores of
0.75 (azelastine 0.05%) and 0.90 (azelastine 0.025%) versus 1.15
(placebo) at 14 days. SD was not available. Petzold 2002 sum-
marised data from three RCTs assessing investigators’ score on
severity of itching; one of these three trials (study ID 3021), with
mean scores of 0.53 (azelastine) versus 1.39 (placebo), had sta-
tistically significant results in favour of the active treatment. The
differences reported in the other two RCTs were not statistically
significant, that is study ID 3062 reported mean scores 0.73 (aze-
lastine) and 0.76 (placebo), and study ID 3034 reported mean
scores 0.76 (azelastine) and 1.10 (placebo).
Four studies presented data for watering eyes or tearing using a
0-3 scale or sum scores of symptoms (Giede-Tuch 1998; James
2003; Lenhard 1997; Sabbah 1998). Giede-Tuch 1998 presented
participant-reported tearing as mean scores (data estimated from
graph) of 0.45 and 0.35 (azelastine 0.05% and 0.025%, respec-
tively) versus 0.55 (placebo) at 14 days. No SD was reported.
Sabbah 1998 used response rates (calculated from participants’
diaries), and Lenhard 1997 reported participants’ tearing scores
using the same 0-3 scale as for itching.
Data on ocular irritation (described as foreign body sensation) and
photophobia were not frequently reported. In James 2003, there
was improvement in both study and control groups, although the
results were not statistically significant. Some studies reported ocu-
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lar irritation and photophobia as part of a composite investigator-
reported sum score, for example Sabbah 1998, in which foreign
body sensation was part of an 8-symptom sum score at days 3 and
14.
Overall symptom scores
One study, Sabbah 1998, reported itching as composite sum score
and response rates on three eye symptoms (itching, tearing, and
conjunctival redness), calculated from participants’ diaries. Two
studies reported participant composite sum score based on two
symptoms (itching and redness) using sum mean score (0-6 scale)
(Canonica 2003; Nazarov 2003), however neither of these studies
reported SD. Nazarov 2003 reported sum score of 1.9 (azelastine)
versus 3.0 (placebo), estimated from a published graph at day 14
and the differences consistently increased in favour of the active
treatment with longer follow-up, until day 42. These results were
consistent with investigators’ assessment reported as statistically
significant. Canonica 2003 reported investigators’ sum scores on
itching and redness with mean scores and SD of 1.8 (1.4) (azelas-
tine) versus 3.1 (1.5) (placebo), with change at day 7 statistically
significant.
Safety outcomes
No serious adverse events or changes in vital signs were reported
during the treatment. Overall, azelastine and placebo were well
tolerated by participants across all the studies; few cases withdrew
from azelastine or placebo groups due to insufficient tolerability
(burning sensation or bitter taste, or both).
Summary
There was some evidence from individual studies that azelastine
improved some symptoms more than placebo. However, it was
not possible to perform formal meta-analyses for this treatment
comparison due to variations of outcomes reported and the lack
of suitable data.
Table 2. Azelastine versus placebo. Outcome definition, time
points, and summary of results
Article Outcome
definition
Time point Azelastine Placebo Number of partici-
pants randomised
(n) and comment
Canonica 2003 Investigator’s assess-
ment
of change in clinical
sum score (itching,
redness) (range 0-6)


















course of sum score of
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SD: standard deviation
3. Levocabastine versus placebo
The search strategy identified five eligible studies comparing
the antihistamine levocabastine versus placebo (Azevedo 1991;
Canonica 2003; Davies 1993; Graue 1994; Sabbah 1998). Four of
these studies included a third arm comparing levocabastine against
azelastine, in Canonica 2003 and Sabbah 1998, and levocabas-
tine against nedocromil sodium or sodium cromoglycate (Azevedo
1991; Davies 1993). Drug concentration was the same in all the
studies, 0.05% or 0.5 mg/ml instilled two to four times a day, but
Canonica 2003 did not specify dose or concentrations.
The number of participants randomised (or analysed if numbers
randomised not known) to levocabastine and placebo were 18
versus 21 (Azevedo 1991), 26 versus 52 (Canonica 2003), 31
versus 32 (Davies 1993), 20 versus 20 (Graue 1994), and 32 versus
30 (Sabbah 1998), respectively.
Duration of treatment was variable: six weeks in two studies (
Canonica 2003; Sabbah 1998), four weeks in two studies (Azevedo
1991; Davies 1993), and one week in one study (Graue 1994).
Primary outcomes
Data on itching were reported in four studies with some variations
in how this symptom was reported. One study did not report it-
ching as a main eye symptom but reported the other three pri-
mary outcomes (Azevedo 1991). Grass pollen counts were counted
daily during the treatment period of some studies (Azevedo 1991;
Davies 1993). Graue 1994 reported only the percentages in vari-
ous severity categories using graphs. There were no statistically sig-
nificant differences between the levocabastine and placebo groups
(P = 0.45) for improvement of itching at 7 days.
Azevedo 1991 collected data on participant-reported ocular irrita-
tion as percentage of days with absence of ocular irritation. Sixty-
three percent had symptom-free days in the levocabastine group
versus 44% after placebo (P < 0.06). Itching was also reported in
a graph using median area under the curve: 14% (levocabastine)
and 29% (placebo) (data estimated from graph). Graue 1994 re-
ported ocular irritation (foreign body sensation), but there was no
statistically significant difference between groups (P = 0.178).
Azevedo 1991 reported tearing as the percentage of days free of
tearing, reporting larger differences during peak pollen days, with
tearing absent in 88% (levocabastine) of the days under treatment
versus 58% (placebo) (P = 0.01). Graue 1994 also reported statis-
tically significant results with improvement of tearing scores (P =
0.006).
Data on photophobia were collected and reported as individual
symptom or as composite sum score. Graue 1994 reported sta-
tistically significant results (P = 0.06) in favour of levocabastine
compared with placebo.
Overall symptom scores
Some studies reported sum scores including itching (Canonica
2003; Sabbah 1998). Canonica 2003 used the mean score for
itching and conjunctival redness (0-6 scale) with mean scores 1.5
(levocabastine) versus 3.85 (placebo) (estimated from a graph),
but SD was not given. Davies 1993 reported percentages of global
efficacy of treatment with significant participant-reported grading
in which participants considered treatment as excellent or good
in 87% (levocabastine) against 63% (placebo) (P = 0.05); similar
results were observed from investigators’ assessed overall score of
efficacy of treatment (91% levocabastine versus 68% placebo).
Safety outcomes
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Overall, levocabastine and placebo were well tolerated by partici-
pants across the studies with no reports of serious adverse events.
No difference was reported in the incidence of adverse events be-
tween the active and placebo groups, however one study reported
higher incidence of (mild) adverse events in the placebo group
compared to the levocabastine group (Graue 1994).
Summary
There was some evidence from individual studies that levocabas-
tine-treated participants had better outcomes than those who re-
ceived placebo. However, it was not possible to perform formal
meta-analyses for this comparison due to variations of outcomes
reported and lack of suitable data.
Table 3. Levocabastine versus placebo. Outcome definition,
time points, and summary of results
Article Outcome definition Time point Levocabastine Placebo Number of partici-
pants randomised (n)
and comment
Azevedo 1991 Investigator’s assess-
ment sum score (oc-
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4. Olopatadine versus ketotifen
The search identified four eligible studies comparing the anti-
histamines olopatadine and ketotifen (Avunduk 2005; Höffling-
Lima 2001; Sarker 2011; Varguez-Rodriguez 2009). One study
was a three-arm trial comparing both olopatadine and ketotifen
with placebo (Avunduk 2005). Drug concentration was the same
in all studies (olopatadine 0.1% and ketotifen 0.025%), except
Höffling-Lima 2001, which used ketotifen 0.05%.
Duration of treatment was four weeks in three studies, Avunduk
2005, Höffling-Lima 2001, and Varguez-Rodriguez 2009, and
two weeks in one study (Sarker 2011).
In all studies the sample size was relatively small. The number
of participants randomised to olopatadine and ketotifen were 16
versus 16 (Avunduk 2005), 20 versus 20 (Höffling-Lima 2001),
46 versus 46 (Sarker 2011), and 20 versus 20 (Varguez-Rodriguez
2009), respectively.
Primary outcomes
Although four studies reported at least two of the four symptoms
prespecified as primary outcomes (itching and tearing), there was
some variation in how these outcomes were reported.
All four studies collected data on participant-reported itching
using a 0-3 scale. Two studies reported mean and SD values
(Avunduk 2005; Sarker 2011).
Two studies did not find any differences between olopatadine
and ketotifen in itching reporting (Avunduk 2005;Höffling-Lima
2001), while two studies found a greater reduction in itching
with olopatadine than with ketotifen after two weeks of treatment
(Sarker 2011; Varguez-Rodriguez 2009). Sarker 2011 reported
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two-week mean scores of 1.09 (SD 0.53) with ketotifen and 0.33
(SD 0.60) with olopatadine. A random-effects meta-analysis of
these four studies showed evidence of a statistically significant dif-
ference in favour of olopatadine in the reduction of itching at 14
days (mean difference (MD) -0.32, 95% confidence interval (CI)
-0.59 to -0.06) (Figure 5). However, there was high statistical het-
erogeneity (I2 = 83%).
Figure 5. Forest plot of comparison: 1 Olopatadine versus ketotifen, outcome: 1.1 Itching at 14 days (0-3
scale)
Two studies presented data for participant-reported ocular irrita-
tion (described in both studies as burning) (Höffling-Lima 2001;
Varguez-Rodriguez 2009). Höffling-Lima 2001 did not find any
differences between groups, while Varguez-Rodriguez 2009 re-
ported a statistically significant greater reduction in burning in the
olopatadine group (P < 0.05).
All four studies reported data on tearing. Only one study reported
differences between groups after twoweeks (Sarker 2011), with the
group treated with olopatadine having less tearing (mean 0.03, SD
0.16) than the one treated with ketotifen (mean 0.40, SD 0.66).
Three studies assessed tearing at 14days (Avunduk 2005;Höffling-
Lima 2001; Sarker 2011). A random-effects meta-analysis of these
studies found no evidence of a difference between olopatadine
and ketotifen (MD -0.06, 95% CI -0.35 to 0.22). There was no
evidence of a difference in the reduction of tearing scores at 14
days between the 2 groups (Figure 6). Once again, there was high
statistical heterogeneity between the studies (I2 = 90%).
Figure 6. Forest plot of comparison: 1 Olopatadine versus ketotifen, outcome: 1.2 Tearing at 14 days (0-3
scale)
We knew of two studies that collected data on photophobia
(Höffling-Lima 2001; Sarker 2011). There were no differences
between groups.
Safety outcomes
No serious adverse events were reported in the four papers. Three
studies did not report any side effects (Avunduk 2005; Höffling-
Lima 2001; Varguez-Rodriguez 2009). In one study, ketotifen was
associated with a mild stinging sensation of short duration (less
than 30 minutes) in 13 out of 43 participants; no participants
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treated with olopatadine reported such discomfort (Sarker 2011).
Overall summary
There was some evidence from individual trials that olopatadine
may be more effective than ketotifen in improving some ocular
symptoms such as itching.
Both drugs are safe.
Table 4. Olopatadine versus ketotifen. Outcome definition,
time points, and summary of results
Article Outcome
definition
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ing and tearing at 2
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5. Emedastine versus levocabastine
We identified three randomised studies that compared the antihis-
tamines emedastine and levocabastine (or levocabastine) (Secchi
2000a; Secchi 2000b; Verin 2001). There was substantial overlap
in the authorship of these three studies, and they had some simi-
larities in study design, outcome measures, and the time points for
clinic visits (days 3, 7, 14, 30, and 42). One study, Secchi 2000a,
was done entirely in a paediatric population (range 4 to 16 years);
the other two studies, although including mainly adults, recruited
participants from a wide range of age groups (range 4 to 76 years).
The same treatment dose (0.05% twice a day) was used in each
study, and treatment lasted for six weeks.
The number of participants randomised to emedastine and levo-
cabastine was 20 versus 22 (Secchi 2000a), 97 versus 105 (Secchi
2000b), and 97 versus 105 (Verin 2001), respectively.
Primary outcomes
All three studies evaluated itching. Secchi 2000a evaluated itch-
ing up to 42 days using a 0-9 scale. At 14 days, mean scores of
0.7 (emedastine) and 2.5 (levocabastine) were obtained (no SD,
estimated from graph). Maximum itching scores from participant
diaries were also reported as always lower for emedastine for this
study, but no actual data were reported. Secchi 2000b also col-
lected itching data at visits and using participant diaries but did
not report any specific data in this article. The authors stated that
emedastine was statistically significantly better than levocabastine
at 4 of the 5 time points evaluated. Using graphs, Verin 2001 re-
ported mean itching and maximum itching (participant diaries)
up to 42 days using a 0-4 scale. At 14 days, mean scores were 1.5
(emedastine) versus 2.3 (levocabastine). For this study, participant
diary scores for maximum itching were 2.0 (emedastine) versus
2.7 (levocabastine).
None of the studies directly evaluated the other primary outcomes
of this review (irritation, watering eyes, and photophobia).
Overall symptom score
Secchi 2000a measured the physician’s overall impression score at
each visit. At 14 days this was 1.1 (emedastine) versus 1.9 (lev-
ocabastine) (no SD, estimated from graph). Secchi 2000b mea-
sured the physician’s overall assessment at the same time points,
stating that emedastine was statistically significantly better than
levocabastine at all 5 time points, but presented no data.
Conclusion
There was only limited information on our primary outcomes, as
these three papers focused on chemosis and eyelid swelling. The
results suggested a benefit in favour of emedastine compared with
levocabastine for itching and overall symptom relief, but despite
some similarities in study design between the three papers, it was
not possible to conduct formal meta-analysis, either because the
studies presented no data or because they provided no SDs. It was
not possible to investigate irritation,watering eyes, or photophobia
as no data were available.
Table 5. Emedastine versus levocabastine. Outcome
definition, time points, and summary of results
Article Outcome definition Time point Emedastine levocabastine Number of participants randomised (n)
and comment
Secchi 2000a Mean physician’s im-
pression score (0-4
scale)
14 days 1.1 1.9 n = 42
Estimated fromgraph, no standard deviation
Secchi 2000b Mean physician’s im-
pression score (0-4
scale)
14 days Not reported Not reported n = 202
“statistically significant” differences
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6. Nedocromil sodium/sodium cromoglycate versus
levocabastine
We identified two randomised studies comparing the mast cell
stabiliser sodium cromoglycate with the antihistamine levocabas-
tine (levocabastine) (Azevedo 1991; Davies 1993). Duration of
treatment was four weeks in both studies, and both studies also
included a placebo arm. We identified no studies comparing ne-
docromil sodium versus levocabastine.
The number of participants randomised (or analysed if numbers
randomised not known) to sodium cromoglycate and levocabas-
tine were 21 versus 18 in Azevedo 1991 and 32 versus 31 inDavies
1993, respectively.
Primary outcomes
Neither study presented data on itching. Davies 1993 collected
daily data on itching from participant diaries, but specifically re-
ported no data.
Azevedo 1991 presented a graph showing daily mean irritation
using a 0-4 scale: at 14 days mean itching was around 1.0 for
sodium cromoglycate and 0.8 for levocabastine, and there were
statistically significant between-group differences in the median
area under the curve for the entire 28-day follow-up period in
favour of levocabastine. Davies 1993 collected information on
ocular irritation but again did not report this information directly.
Azevedo 1991 reported that the median area under the curve for
tearing was similar in each group. Although the study provided
no data, Davies 1993 reported that tearing was statistically signif-
icantly lower for levocabastine.
For photophobia, Azevedo 1991 reported similar change scores
from baseline for the two groups. Davies 1993 did not report any
information on this outcome.
Overall symptom score
Davies 1993 collected the participant and investigator global
evaluation of treatment efficacy using a 4-point scale (Table 6).
Azevedo 1991 reported the investigator assessment using a sim-
ilar scale. In each study there was a similar statistically signifi-
cant difference in the proportion rated as excellent or good by
the investigator in favour of levocabastine: Azevedo 1991 (ne-
docromil sodium: 67%, levocabastine: 89%); Davies 1993 (ne-
docromil sodium: 68%, levocabastine: 91%) (Table 6).
Davies 1993 also reported that participants treated with levo-
cabastine were statistically significantly more likely to be “virtually
symptom-free”.
Overall summary
We identified only two randomised studies for this comparison.
Although these studies collected data for most of the primary out-
comes of this review, the data were either not reported or not given
in a format suitable for meta-analysis. Both studies reported a dif-
ference of over 20% in favour of levocabastine in those rating the
overall treatment efficacy as good or excellent. Although some sta-
tistically significant differences were reported suggesting increased
efficacy of levocabastine compared with nedocromil sodium, this
finding needs to be treated with caution.
Table 6. Nedocromil sodium/sodium cromoglycate versus
levocabastine. Outcome definition, time points, and
summary of results
Article Outcome definition Time point Nedocromil sodium /
sodium cromoglycate
Levocabastine Number of partic-
ipants randomised (n)
and comment
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can be estimated from
graph, and mean score
could be calculated if
considered appropriate
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7. Azelastine versus levocabastine
We identified two randomised studies comparing the antihis-
tamines azelastine and levocabastine (Canonica 2003; Sabbah
1998). Both studies also included a placebo group. The duration
of treatment was six weeks in Canonica 2003 and two weeks in
Sabbah 1998.
The number of participants randomised (or analysed if numbers
randomised not known) to azelastine and levocabastine were 57
versus 26 in Canonica 2003 and 51 versus 32 in Sabbah 1998,
respectively.
Primary outcomes
In both studies itching was assessed by both investigators and
participants (using diaries), but no results were directly reported.
Canonica 2003 reported only a composite score of itching and
redness. Sabbah 1998 only reported itching as part of two com-
posite scores comprising three and eight eye symptoms.
Sabbah 1998 only reported the other primary outcomes as part
of composite symptom scores. Tearing (tearing) was reported in
both composite scores. Foreign body sensation and photophobia
were included as part of the eight-item score.
Overall symptom score
The composite symptom scores reported by the two studies were
different. Canonica 2003 used the sum of itching and redness
(range 0-6). At 14 days themean scores from the participant diaries
(estimated from a graph) were around 1.6 (azelastine) versus 1.4
(levocabastine). The investigator-reported composite scores at 7
and 21 days were also similar in each group. The participant-
reported scores were only reported in terms of the proportion of
participants improving.
Sabbah 1998 used two composite scores: the first comprised three
symptoms (itching, conjunctival redness, and tearing; range 0-9);
the second added five additional symptoms (swollen eyelids, for-
eign body sensation, photophobia, soreness, and discharge/eyelids
sticking together). At day 13 scores for the 3-item score (estimated
from a graph) were around 1.8 (azelastine) versus 1.5 (levocabas-
tine). The study presented additional results for the numbers re-
sponding by day three of treatment.
Overall summary
Overall, there was no clear evidence of differences between azelas-
tine and levocabastine in either study (Table 7).
Table 7. Azelastine versus levocabastine. Outcome definition,
time points, and summary of results
Article Outcome definition Time point Azelastine Levocabastine Number of participants randomised (n)
and comment
Canonica 2003 Itching and redness
(range 0-6)
14 days 1.6 1.4 n = 139
Estimated from a graph (no SD)
Sabbah 1998 Itching, conjunctival
redness, and tearing
(range 0-9)
13 days 1.8 1.5 n = 113
Estimated from a graph (no SD). A further




8. Olopatadine versus placebo or other control
The search identified two eligible studies comparing the antihis-
tamine olopatadine versus placebo, in Avunduk 2005, or other
control, in Lanier 2001.
The Avunduk 2005 study was a three-arm trial comparing both
olopatadine and ketotifen with placebo (Avunduk 2005). Dura-
tion of treatment was four weeks, but two-week data were avail-
able. The sample size was relatively small, with 16 participants
randomised to olopatadine and 17 participants randomised to ar-
tificial tears (placebo). Mean and SD data were available.
Lanier 2001 compared the effect of topical olopatadine in peo-
ple undergoing treatment with an oral antihistamine (loratadine).
Duration of treatment was one week. A total of 94 participants
(49 versus 45) were randomised but not masked. No SD data were
available.
Primary outcomes
Avunduk 2005 reported two of the four symptoms prespecified
as primary outcomes (participant-reported itching and watering
eyes). Data on mean and SD were available. Olopatadine had
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statistically significantly less severe itching (mean 0.76, SD 0.1)
and tearing (mean 0.30, SD 0.1) than the placebo group (mean
itching 1.85, SD 0.3; mean tearing 1.07, SD 0.2) after two weeks
of treatment.
Lanier 2001 included participant-reported itching on a 4-point
scale (from 1 to 4). After one week, reported itching was less in
the group treated with olopatadine (mean 2.21 versus 2.74, P =
0.044).
Safety outcomes
There were no adverse events or side effects associated with
olopatadine in either study.
Overall summary
There was evidence from two small trials that olopatadine may be
effective in improving some ocular symptoms.
Table 8. Olopatadine versus control. Outcome definition,
time points, and summary of results
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9. Nedocromil sodium or sodium cromoglycate versus
azelastine
We identified a single randomised study comparing the mast cell
stabiliser sodium cromoglycate with the antihistamine azelastine
(James 2003). This study also included a placebo arm. The origi-
nal numbers randomised was not clear, but the analysis included
50 (sodium cromoglycate) versus 45 (azelastine) participants. Du-
ration of treatment was two weeks.
Primary outcomes
Unfortunately this study did not directly report any of our pre-
specified outcomes at follow-up, although it did report results for
itching, foreign body sensation, and photophobia in terms of the
improvement rates from baseline to day three. Improvement rates
were higher for azelastine for all eight symptoms examined.
Overall symptom score
James 2003 also reported 2 composite symptom scores comprising
3 main symptoms (itching, redness, and tearing): an investigator-
reported score and composite symptom scores from participant
diaries up to 14 days. Scores were similar in each group.
The study reported response rates to treatment by day 3 (a decrease
of at least 3 points in the composite symptom score) to be 39 out
of 47 (83%) for sodium cromoglycate and 35 out of 41 (85%) for
azelastine.
Overall summary
The evidence for this comparison came from a single study, and al-
though the study reported results for ocular symptoms, the results
were not in the format prespecified for this review. Overall, there
was no clear evidence of a difference between the two treatments.
10. Levocabastine versus antazoline plus tetryzoline
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We identified a single randomised study comparing the antihis-
tamine levocabastine (n = 35) versus the antihistamine antazoline
plus tetryzoline (a derivative of imidazoline) (n = 34) (Wertheimer
1997).
Primary outcomes
The study reported no data on the four primary outcomes of
this review (itching, irritation, watering eyes, and photophobia).
However, all four symptoms were included as part of an overall
symptom score.
Overall symptom score
The study presented a total symptom score (range 0-24) com-
prising four subjective (itching, foreign body feeling, tearing, and
photophobia) and four objective (hyperaemia, follicles, chemosis,
and swollen eyelid) symptoms. At day 15, mean scores were 2.0
for levocabastine and 3.0 for antazoline plus tetryzoline. These
results were estimated from a graph, and no SDs were presented.
There were no significant differences between the groups at days
4 and 15, although the antazoline/tetryzoline group was favoured
when assessed 30 minutes after application.
Overall summary
Evidence for this comparison comes from one relatively small ran-
domised study.Therewere no clear differences between the groups.
11. Ketotifen versus placebo
The search identified one eligible study comparing the antihis-
tamine ketotifen versus placebo (Avunduk 2005). This study was
a three-arm trial comparing both olopatadine and ketotifen with
placebo.
Duration of treatment was four weeks.
The sample size was relatively small, with 16 participants ran-
domised to ketotifen and 17 participants randomised to artificial
tears (placebo).
Primary outcomes
The study reported two of the four symptoms prespecified as pri-
mary outcomes (itching and watering eyes). Data on mean and
SD were available.
Ketotifen had statistically significantly less severe itching (mean
1.08, SD 0.2) and tearing (mean 0.17, SD 0.1) than the placebo
group (mean itching 1.85, SD 0.3; mean tearing 1.07, SD 0.2)
after two weeks of treatment.
Safety outcomes
No adverse events or side effects were reported.
Overall summary
There is evidence froma small individual trial that ketotifenmay be
more effective than placebo in improving some ocular symptoms.
12. Olopatadine versus nedocromil sodium
The search identified one eligible study comparing the anti-
histamine olopatadine with the mast cell stabiliser nedocromil
sodium in a parallel-group trial where one group used olopatadine
and placebo and the other nedocromil sodium (Katelaris 2002).
Duration of treatment was six weeks. The sample size was rela-
tively large, with 91 participants randomised to the olopatadine
group and 94 participants randomised to the nedocromil sodium
group; analysis was only performed on 82 and 87 participants,
respectively. In the olopatadine group, participants were treated
with olopatadine 0.1% (in the morning and evening) and placebo
(at noon and afternoon); in the nedocromil sodium group, partic-
ipants were treated with nedocromil sodium 2%. The study pro-
vided no information on howmany participants were randomised
within each treatment group.
Primary outcomes
The study reported one of the four symptoms prespecified as pri-
mary outcomes (itching). Participants recorded itching and red-
ness on a scale of 0 to 9 (9 being more severe). After two weeks,
mean itching score of participants taking olopatadine was 1.9,
compared to 2.5 in those taking nedocromil sodium (P < 0.05).
However, there was no significant statistical difference in redness
scores at 14 days.
The study reported that the likelihood of a day without eye red-
ness and itching was 1.6 times greater on most days in partic-
ipants treated with olopatadine compared to those treated with
nedocromil sodium. This difference was recorded as constant over
time (P < 0.001).
Safety outcomes
In the olopatadine group, four cases of treatment-related adverse
events were recorded (ocular discharge, stinging, and blurred vi-
sion). Two participants experienced dry nose and taste perversion.
In the nedocromil sodium group, five participants experienced
treatment-related ocular adverse events (dry eye, stinging, itching,
and tearing).
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Overall summary
This study suggested there is some evidence supporting olopata-
dine as a more effective agent than nedocromil sodium in improv-
ing some ocular symptoms of allergic conjunctivitis.
13. Ketotifen versus levocabastine
The search identified one eligible study comparing the antihis-
tamine ketotifen (0.025%) with the antihistamine levocabastine
(0.05%) (Kidd 2003). The study was a three-arm trial comparing
both ketotifen and levocabastine to placebo in a large, multicentre
trial.
Duration of treatment was four weeks.
The sample size was large, with a total of 519 participants being
randomised to 1 of 3 groups: 172 participants were randomised to
ketotifen and 174 participants were randomised to levocabastine.
Primary outcome
This study reported only two of the prespecified primary outcome
measures (participant-reported itching and watering). Participant-
recorded data was only available for days one to four. Participants
scored itching on a 5-point scale (4 beingmost severe) andwatering
on a 4-point scale (3 being severe).
At day 4, mean score of itching for ketotifen was the lowest (1.4),
compared with 1.7 for both levocabastine and placebo (P < 0.05).
The mean score of watery eyes for participants treated with keto-
tifen was the lowest (0.75) after 4 days compared with 1.2 for par-
ticipants treated with both placebo and levocabastine (P < 0.05).
Safety outcomes
The study recorded four serious adverse events. In the placebo
group, two participants experienced persistent photophobia and
conjunctivitis with corneal ulcer. In the ketotifen group, two par-
ticipants experienced spontaneous pneumothorax and abdominal
pain, which was probably not due to the drug.
Overall summary
This study showed some evidence that ketotifen may be superior
in alleviating some ocular symptoms of allergic conjunctivitis.
14. Combined levocabastine hydrochloride and pemirolast
potassium versus levocabastine hydrochloride alone
The search identified one eligible study comparing a combination
of the antihistamine levocabastine hydrochloride (0.025%) oph-
thalmic suspension and pemirolast potassium solution with levo-
cabastine (0.025%) alone (Fujishima 2008).
Duration of treatment was one week.
The sample size was small, with 15 participants randomised to
the combined treatment group and 17 participants randomised to
single-agent treatment.
Primary outcomes
The study reported two of the four symptoms prespecified as pri-
mary outcomes (itching, tearing). The study collected data by par-
ticipant diary and visual analogue scale quantified by the partici-
pant. Data on mean and SD was available.
After one week of treatment there was a reduction in mean (SD)
itching in both combined-treatment (-4.6 (2.3)) and single-treat-
ment (-2.8 (2.8)) groups. There was no significant difference in
alleviation of symptoms between the groups (P = 0.079).
Only 11 participants in the single-treatment group and 8 partic-
ipants in the combined-treatment group had symptoms of tear-
ing. The degree of reduction in tearing (mean (SD)) was more
statistically significantly in the combined-treatment group com-
pared with the single-treatment group (-4.0 (2.6) vs. -1.5 (0.9), P
= 0.008).
Safety outcomes
No adverse reactions were observed in either group.
Overall summary
There was some evidence from a single study with a small sample
size that levocabastine in combination with pemirolast potassium
may be more effective in eliminating some symptoms when com-
pared with levocabastine alone.
15. Levocabastine versus mequitazine
The search identified one randomised study as an abstract (full
text was not available) comparing the antihistamine levocabastine
(0.05%) versus the antihistamine mequitazine (0.05%) eyedrops
in a parallel-group trial (Trinquand 1999).
The study did not report the numbers randomised to each group,
but reported that a total of 357 participants were randomised.
Duration of treatment was four weeks (doses were twice a day for
the first week and two or three times daily for three weeks).
Primary outcomes
Ocular symptoms were assessed by the investigator and partici-
pants (diary cards). Investigator assessment was good or excellent
in 72% ofmequitazine-treated participants and 70% of levocabas-
tine-treated participants.
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Safety outcomes
The study reported fewer adverse events in the mequitazine group
(P < 0.05).
The overall safety of mequitazine (0.05%) was significantly better
than levocabastine.
Overall summary
There was some evidence from a single study with a large sample
size (n = 357) that mequitazine is as effective as levocabastine in
teenagers and adult patients.
16. Bepotastine besilate versus olopatadine
The search identified one eligible study comparing the antihis-
tamine bepotastine besilate ophthalmic solution (BBOS) against
the antihistamine olopatadine, an investigator-masked, single-cen-
tre, cross-over study that randomised 30 participants (McCabe
2012). Participants were not masked.
The duration of treatment was two weeks, followed by a seven-
day washout period. After the washout period, participants were
crossed-over to the alternative treatment for two additional weeks.
Although a paired t-test was used to analyse this study, no paired
datawere presented. Some resultswere obtainable fromgraphs, but
these were assumed to represent mean (SD) values after pooling
data from both the first and second periods of the study. This
meant that unit of analysis issues would have been a potential
concern when combining with participant-randomised studies.
However, no meta-analyses were possible for this comparison.
Primary outcomes
Participants assessed ocular itching during the three clinic visits
using a 5-point Likert scale (1 = lowest relief, 5 = highest relief )
and used a daily home diary to assess ocular itch relief twice a day
(morning and evening) over two weeks of treatment.
Rather different mean (SD) results were obtained for the morn-
ing and evening (morning: BBOS 4.04 (0.12) versus olopatadine
4.10 (0.15); evening: BBOS 4.04 (0.12) versus olopatadine 3.90
(0.12)). These results appeared to be for both periods of the cross-
over study combined.
Safety outcomes
The study reported no serious adverse events. About 10% of the
participants treated with BBOS 1.5% reported a mild, temporary
adverse taste after instillation.
Overall symptom score
The study reported the mean (SD) rating of each treatment’s abil-
ity to relieve all ocular-related allergy symptoms (1 = lowest relief,
3 = highest relief ) for morning and evening separately (morning:
BBOS 2.30 (0.1) versus olopatadine 2.25 (0.15); evening: BBOS
2.30 (0.1) versus olopatadine 2.15 (0.15)). From the participants’
diary responses, BBOS 1.5% was significantly more effective at re-
lieving morning and evening ocular allergy symptoms (P = 0.032
and P < 0.0001, respectively) compared to olopatadine hydrochlo-
ride 0.2%.
Overall summary
There was insufficient evidence to compare the efficacy of BBOS
against olopatadine, as we found only one study with a small sam-
ple size that was judged to be at high risk of bias, as participants
were not masked to treatment allocation.
17. BBOS versus placebo
The search identified a single multicentre, randomised trial com-
paring the antihistamine BBOS against placebo (Carr 2013). The
study randomised participants to receive either BBOS (n = 123)
or placebo (n = 122) twice a day for a period of two weeks.
Primary outcomes
Participants assessed ocular itching twice a day using a 4-point
scale (0 = absent, 3 = severe) that was part of the participant out-
comes assessed from a Rhinoconjunctivitis Quality of Life Ques-
tionnaire. The study reported results as percentages of improve-
ment from baseline (instantaneous -- approximately 15 minutes
before scoring, and reflective -- last dosing throughout the 2-week
treatment period) of ocular itching scores over the treatment pe-
riod. The mean change from baseline involved taking the daily
average of a two-week period and comparing with themean scores
from a three-day baseline period. For reflective itching, mean im-
provements were 28.0% for BBOS and 21.1% for placebo. For
instantaneous itching,mean improvements were 28.3% for BBOS
and 20.3% for placebo.
Safety outcomes
The study reported no serious adverse events. More mild adverse
events were reported in the BBOS group (29 participants) than in
the placebo group (11 participants). Themost frequently reported
adverse events in the BBOS group were bitter taste (14 partici-
pants in the BBOS group, 1 participant in the placebo group) and
instillation site pain.
Overall summary
There was some evidence from a single trial with a large sample
size (n = 245) that BBOS is more effective at improving ocular
itching than placebo. However, full results other than percentage
change in itching scores were not available.
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D I S C U S S I O N
Summary of main results
We identified 30 trials with 17 different treatment comparisons
evaluating the efficacy and safety of topical antihistamines and
mast cell stabilisers, either alone or in combination. The following
antihistamines and mast cell stabilisers were evaluated in at least
one randomised controlled trial: nedocromil sodium or sodium
cromoglycate, olopatadine, ketotifen, azelastine, emedastine, lev-
ocabastine or levocabastine, combination of antazoline and tetry-
zoline, combination of levocabastine and pemirolast potassium,
and bepotastine besilate. The most common comparison was aze-
lastine versus placebo (nine studies). Unfortunately, formal meta-
analysis was only possible for two outcomes in one comparison
(olopatadine versus ketotifen, itching and tearing at 14 days), and
the results should be interpreted with caution due to the high sta-
tistical heterogeneity, both for itching (I2 = 83%) and tearing (I2
= 90%). For this comparison, one study differed from the other
studies as it favoured olopatadine (Sarker 2011).
The inability to meta-analyse other results was mainly due to the
variety of outcome measures reported and the fact that standard
deviations were often not provided. Due to the presence of a net-
work of different treatments in this review, this should have been
an ideal situation to conduct a network meta-analysis of overall
symptom scores, but the heterogeneity in outcome definitions and
time points and the lack of standard deviations meant that sadly,
this was not feasible. We did not do sensitivity analysis because of
the small number of studies involved in the meta-analysis.
There was some evidence to support the ability of topical antihis-
tamines to reduce symptoms and signs of seasonal allergic con-
junctivitis when compared with placebo. There were no serious
adverse events related to the use of topical antihistamine treat-
ment.
When comparing different types of antihistamines and mast cell
stabilisers, there were limited data to inform if some treatments are
more effective than others. Results from a meta-analysis suggested
that olopatadine may be more effective than ketotifen in relieving
itching, although there was high statistical heterogeneity between
the two studies. Results from individual studies suggested better
outcomes with emedastine, sodium cromoglycate, and ketotifen
when compared with levocabastine. A single study suggested a
benefit of olopatadine over sodium cromoglycate.
Overall completeness and applicability of
evidence
There are no long-term studies on the efficacy of topical antihis-
tamines for the treatment of seasonal allergic conjunctivitis, and
little evidence to compare antihistamines.
Quality of the evidence
Poor quality of reporting challenged the synthesis of evidence.
We observed a large variability in reporting outcomes. The overall
quality of the studies and reporting was poor, and most studies
had small sample sizes. Trials only evaluated short-term effects,
with a range of treatment of one to eight weeks.
Potential biases in the review process
None. This review was performed to Cochrane standards.
Agreements and disagreements with other
studies or reviews
We are not aware of any other similar reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Topical antihistamines and mast cell stabilisers reduce symptoms
and signs of seasonal allergic conjunctivitis when compared with
placebo in the short term.Overall, topical antihistamines andmast
cell stabilisers appear to be safe and well tolerated. There is poor
evidence to compare efficacy among different antihistamines and
mast cell stabilisers.
Implications for research
Methodological research to reach consensus on core outcomemea-
sures and how best to quantify them would facilitate research in
this area. Large trials comparing the efficacy of different antihis-
tamines and mast cell stabilisers would be required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Avunduk 2005
Methods Parallel-group RCT
Participants 49 participants recruited with seasonal allergic conjunctivitis
Interventions Three treatment arms: ketotifen 0.025% ophthalmic solution; olopatadine hydrochlo-
ride 0.1% ophthalmic solution; artificial tear substitute (preservative free). Duration of
treatment 30 days, follow-up 30 days (2-month study)
Outcomes Participant evaluation of ocular symptoms (itching, tearing)
Investigator assessment of ocular signs (redness, eyelid swelling, chemosis)
Mean scores (using a scale range 0-3; 0 = none, 3 = severe)
Time points: at day 0, 15, and 30 of treatment
Country Turkey
Number randomised, gender (male:fe-
male)
39 participants randomised. M:F 20:19
Age mean (SD), median, range Overall range 18-61 years
Notes Study conducted from April to May 2004. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list (p.1394 - study medications): “Eligible
patients were randomly assigned, in a 1:1 ratio using a computer-
generated list of random numbers...”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported for each intervention group with
20% lost to follow-up (Figure 1 in the trial report), reasons were
not given. A similar number of participants were lost to follow-
up in each arm
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
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Avunduk 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants (p.1394 - studymedications): “Tomain-
tain masking, all medications had identical packaging, color,
consistency, pH, and texture”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators masked (p.1394 - efficacy assessments): “...ocular
signs (redness, eyelid swelling, and chemosis) were graded, using
slit-lamp examination and ordinal grading scales, by an investi-
gator masked to treatment assignment.”
Azevedo 1991
Methods Parallel-group RCT
Participants 63 participants recruited with moderate or severe allergic conjunctivitis
Interventions Three treatment arms: levocabastine 0.5 mg/ml eye drops; sodium cromoglycate 20 mg/
ml eye drops; placebo eye drops. Duration of treatment 28 days
Outcomes Participant assessment (ocular irritation, redness, photophobia, tearing, swollen eyelids,
conjunctival oedema using a 4-point scale; 0 = none, 3 = severe)
Investigator assessment (ocular irritation, redness, photophobia, tearing, swollen eyelids,
conjunctival oedema, using a 4-point scale; 0 = none, 3 = severe)
Time points: at baseline and day 14 and 28 of treatment
Country Portugal
Number randomised, gender (male:fe-
male)
63 participants randomised, 60 participants analysed. M:F 24:36
Age mean (SD), median, range Median (range): levocabastine 27 years (13-55); sodium cromoglycate 26 years (9-46);
placebo 34 years (12-51)
Notes Not reported when study was conducted. Source of funding not reported. Declaration
of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list (p.691 - treatment and methods): “Pa-
tients were randomly allocated (on the basis of a computer-gen-
erated list) to three groups...”
Allocation concealment (selection bias) Unclear risk Method used to conceal the allocation sequence was not de-
scribed
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Azevedo 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and the reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.691 - treatment and methods): “The trial
featured a doubled-blind, parallel groups design”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.691 -treatment andmethods): “The trial fea-
tured a doubled-blind, parallel groups design”
Canonica 2003
Methods Parallel-group RCT
Participants 139 participants recruited with moderate to severe perennial allergic conjunctivitis
Interventions Three treatment arms: azelastine 0.05% eye drops; placebo eye drops; levocabastine eye
drops. Duration of treatment 6 weeks
Outcomes Investigator assessment (itching and redness). Change in clinical sum score (itching and
redness using a scale range 0-6)
Participant assessment of ocular symptoms (daily diaries using a 4-point scale; 0 = none,
3 = severe symptoms)
Time points: at baseline and day 7, 21, and 42 of treatment
Country France, Italy, Spain, Russia, and United Kingdom
Number randomised, gender (male:fe-
male)
139 participants randomised. M:F 65:74
Age mean (SD), median, range Mean (SD): azelastine group 34 years (13.7); placebo group 36 years (13.0); levocabastine
34 years (13.2)
Notes Study conducted from 2December 1998 to 16 June 1999. Source of funding: University
of Genoa, Italy and Clinical and Biometrical Development, VIATRIS GmbH & Co.
KG. Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Canonica 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation code (p.323 - drugs): “A predefined randomisa-
tion code was used to assign azelastine, placebo or levocabastine
treatment to qualified patients in an unbalanced fashion (ratio
2:2:1).”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and the reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.323 - drugs): “Both azelastine eye drops and
the matching vehicle containing placebo were provided by VI-
ATRIS GmbH in identical packaging.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.323 - drugs): “Both azelastine eye drops and
the matching vehicle containing placebo were provided by VI-
ATRIS GmbH in identical packaging.”
Carr 2013
Methods Parallel-group RCT
Participants 245 participants recruited with allergic conjunctivitis
Interventions Two treatment arms: bepotastine besilate (BBOS) eye drops 1.5%; placebo eye drops.
Duration of treatment 2 weeks
Outcomes Participant assessment of ocular itching (instantaneous and reflective)mean change scores
(using diaries and a 4-point scale; 0 = none, 3 = severe)
Time points: at baseline, day 7 and 14 after treatment
Country United States
Number randomised, gender (male:fe-
male)
245 participants randomised. M:F 92:153
Age mean (SD), median, range Mean (SD) BBOS group 38.7 (13.80) range 12-85; placebo group 41.6 (15.03) range
12-72
Notes Source of funding: ISTA Pharmacologicals. The main investigators declared they had
no financial interests in the outcome of the clinical trial. Carr and Ratner also declared
that they were speakers and consultants for ISTA and Meda Pharmaceuticals
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Carr 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list (p.249 - clinical trial
design): “...were assigned to receive BBOS 1.5% or placebo in a
1:1 ratio as determined by a computer-generated randomisation
list.”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10 % lost to
follow-up, and the reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants (p.249 - clinical trial design): “Both test
agents were provided in identical packaging and manufactured
by Bausch & Lomb (Tampa, FL).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study conducted from July toOctober 2010. Investigatorsmask-
ing (p.249 - clinical trial design): “Subjects were instructed to
instill the double-masked test agent...”
Davies 1993
Methods Parallel-group RCT
Participants 95 participants recruited with allergic conjunctivitis
Interventions Three treatment arms: levocabastine 0.5mg/ml; sodiumcromoglycate 20mg/ml; placebo
eye drops. Duration of treatment 28 days
Outcomes Investigators’ and participants’ assessment of ocular symptoms (4-point qualitative scale:
excellent, good, moderate, poor)
Time points: at baseline, day 14 and 28 after treatment
Country United Kingdom
Number randomised, gender (male:fe-
male)
95 participants randomised. M:F 40:49
Age mean (SD), median, range Mean (range) levocabastine 30 years (7-66); sodium cromoglycate 31 years (10-69);
placebo 30 years (13-61)
38Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Davies 1993 (Continued)
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentages given (numerators/denominators unclear)
Selective reporting (reporting bias) High risk P values given for selected outcomes
Other bias Unclear risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.520 - methods): “…95 patients participated
in this double-blind, parallel group trial.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.520 - methods): “…95 patients participated
in this double-blind, parallel group trial.”
Fujishima 2008
Methods Parallel-group RCT
Participants 32 participants recruited with seasonal and perennial allergic conjunctivitis
Interventions Two treatment arms: levocabastine; levocabastine and pemirolast potassium. Duration
of treatment 1 week
Outcomes Participants used a diary to quantify ocular symptoms (itching, foreign body sensation,
tearing, eye discharge, and hyperaemia) using visual analogue scale
Investigators used a 4-point scale (0 = none, 3 = severe) for quantifying ocular signs:
conjunctival hyperaemia, conjunctival oedema, eyelid oedema, conjunctival papilla for-
mation, and superficial punctate keratopathy
Time points: at baseline and 1 week after treatment
Country Japan
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Fujishima 2008 (Continued)
Number randomised, gender (male:fe-
male)
32 participants randomised, 30 participants analysed. M:F 9:23
Age mean (SD), median, range Mean (range): levocabastine 50.9 years (12-81); levocabastine and pemirolast potassium
40.5 years (7-73)
Notes Not reported when study was conducted. Source of funding unclear. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed-envelope technique (p.233 - test agents): “The patients
were randomly allocated to one of two groups by a sealed-en-
veloped technique…”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data of all participants randomised was analysed and reported
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study did not describe details on masking of participants
on the intervention allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study did not describe details on masking of personnel/
investigators on the intervention allocations
Giede-Tuch 1998
Methods Parallel-group RCT
Participants 151 participants with seasonal allergic conjunctivitis or rhinoconjunctivitis for at least 1
year
Interventions Three treatment arms: azelastine 0.025%; azelastine 0.05%; placebo. Duration of treat-
ment 14 days
Outcomes Participant-assessed itching, tearing, and redness. Sum score (itching, tearing, redness)
and rates of decreased scores by at least 3 score points between day 0-3 using a 4-point
scale (0 = none, 3 = severe) were used
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Giede-Tuch 1998 (Continued)
Investigator-assessed itching, tearing, and redness. A composite sum symptom mean
score (itching, tearing, redness) using a 4-point scale (0 = none, 3 = severe) was analysed
Time points: at baseline, day 3, 7, and 14 after treatment
Country Germany
Number randomised, gender (male:fe-
male)
151 participants randomised, 129 participants analysed. M:F 66:85
Age mean (SD), median, range Mean (SD) azelastine 0.025% 35.4 years (11.4); azelastine 0.05% 35.2 years (10.7);
placebo 35.9 years (11.5)
Notes Study conducted fromMarch to September 1994. Source of funding not stated. Decla-
ration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 15 % lost to
follow-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.858 - study design): “The investigation was
performed as a double-blind, randomized, placebo-controlled
study…”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.858 - study design): “The investigation was




Participants Participants from 5 to 20 years old with seasonal conjunctivitis
Interventions Two treatment arms: levocabastine 0.5 mg/ml; placebo. Duration of treatment 7 days
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Graue 1994 (Continued)
Outcomes Participants’ assessment of ocular symptoms (visual analogue scale; 0 = none, 10 = worse
possible)
Investigator-evaluated symptoms (absent, mild, moderate, and severe)
Time points: at baseline and day 7 after treatment
Country Mexico
Number randomised, gender (male:fe-
male)
40 participants randomised. M:F 30:10
Age mean (SD), median, range Age mean: levocabastine 9.1 years; placebo 10.1 years
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described (p.37 - material and methods): “patients were divided
randomly into two groups…”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.37 - material and methods): “The study de-
sign is double-blind, prospective and comparative...”
“both drugs were provided by Janssen Pharmaceutical in similar
plastic bottles of 4ml each, labeled as levocabastine (including
the ones that contained placebo) and with an identification code
number…”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.37 - material and methods): “The study de-
sign is double-blind, prospective and comparative...”
“both drugs were provided by Janssen Pharmaceutical in similar
plastic bottles of 4ml each, labeled as levocabastine (including
the ones that contained placebo) and with an identification code
number…”
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Hechanova 1984
Methods Parallel-group RCT
Participants 40 participants with allergic conjunctivitis
Interventions Two treatment arms: sodium cromoglycate; placebo. Duration of treatment 4 weeks
Outcomes Participants’ and clinicians’ assessment of ocular symptoms and opinion of efficacy of
treatment: specifically they assessed itching, soreness, redness, grittiness, photophobia
using a 5-point scale (0 = none, 5 = very severe)
Time points: at 1, 2, and 4 weeks after treatment
Results of photophobia were not reported
Country Philippines
Number randomised, gender (male:fe-
male)
40 participants randomised. M:F 20:20
Age mean (SD), median, range Mean (range) 35 years (5-71)
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described (p.60 - material and methods): “...with patients ran-
domly allocated to receive...”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of withdrawals
Selective reporting (reporting bias) High risk Only selected results were presented
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.60 - material and methods): “The trial was
a double-blind group comparison...”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.60 -material and methods): “The trial was a
double-blind group comparison...”
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Höffling-Lima 2001
Methods Parallel-group RCT
Participants 40 participants with allergic conjunctivitis
Interventions Two treatment arms: ketotifen 0.05%; olopatadine 0.1%. Duration of treatment 30 days
Outcomes Participants’ assessment of severity of ocular symptoms: itching, burning, watering, dis-
charge, photophobia (4-point scale; 0 = none, 3 = severe)
Investigator assessment of ocular signs
Time points: at days 1, 2, 7, 14, and 30 after treatment
Country Brazil
Number randomised, gender (male:fe-
male)
40 participants randomised, 34 participants analysed. M:F 15:19
Age mean (SD), median, range Mean (range) 27 years (5-73)
Notes Study conducted from 1 February to 30 June 1999. Source of funding not stated. The
authors declared no commercial interest in the drugs evaluated and did not receive any
direct or indirect benefit or financial support for this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation (p.416 - methods): “A masked and randomised
clinical study was conducted...”
“the introduction of treatment was randomized beforehand...”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with 15% lost to follow-up, and
reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants (p.416 - methods): “A masked and ran-
domised clinical study was conducted...”
“... and bottles with topical medications were masked by oph-
thalmos laboratory.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking of investigator (p.417 - methods): “only the medical
monitors delivered the drugs to patients...”
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James 2003
Methods Parallel-group RCT
Participants 144 participants with seasonal allergic conjunctivitis
Interventions Three treatment arms: azelastine; sodium cromoglycate; placebo. Duration of treatment
14 days
Outcomes Participants’ assessment of symptoms (composite score): itching, redness, tearing, foreign
body sensation, photophobia, soreness, discharge (range 0-9) using participant’s diary
during treatment (14 days)
Investigator assessment of itching, tearing, conjunctival redness (range 0-9, composite
sum score)
Time points: at day 3, 7, and 14 after treatment
Country Germany and United Kingdom
Number randomised, gender (male:fe-
male)
144 participants randomised, 136 participants analysed. M:F 51:93
Age mean (SD), median, range Mean (range): azelastine 37.1 years (16-65); sodium cromoglycate 35.5 years (18-65);
placebo 35.8 years (18-64)
Notes Study conducted from April to September 1995. Source of funding: ASTA Medica AG
(now VIATRIS GmbH&Co. KG). Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Partial double-masked (p.314 - study design): “partial double-
blind, parallel-group... The appearance and application regimen
of placebo eye drops was identical to azelastine and the study
was double-blind in this respect.”
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James 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Partial double-masked (p.314 - study design): “However, the
study was open in respect of sodium cromoglycate-treated pa-
tients where the bottle size and dosage regimen identified this
treatment to the investigator.”
Katelaris 2002
Methods Parallel-group RCT
Participants 188 participants with seasonal allergic conjunctivitis
Interventions Two treatment arms: olopatadine hydrochloride 0.1%; cromolyn sodium 2% (ne-
docromil sodium). Duration of treatment 6 weeks
Outcomes Investigator’s assessment of ocular signs and symptoms: mean ocular symptom scores of
itching and redness and physicians’ impression scale scores, per protocol data (5-point
scale; 0 = none, 4 = very frequent)
Participants’ assessment of itching and redness using diary (10-point scale; 0 = none, 9
= severe)
Time points: at days 1 to 14, and 30 to 42 after treatment
Country 6 European countries and Australia
Number randomised, gender (male:fe-
male)
188 participants randomised, 185 participants analysed. M:F 103:82
Age mean (SD), median, range Mean (SD): olopatadine 33.0 years (19.3); cromolyn sodium 36.8 years (20.9)
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated (p.1563 - study procedures): “A computer-
generated randomization schedule was used to assign sequencial
patients to the study treatments in an equal ratio.”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Analysis per-protocol participants not intention-to-treat analy-
sis. Less than 10% lost to follow-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of adequate outcome reporting
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Katelaris 2002 (Continued)
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masking (p.1563 - study procedures): “Double-masking
was ensured through the use of identical opaque bottles and
similar-appearing contents and labeling.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double masking (p.1563 - study procedures): “Double-masking
was ensured through the use of identical opaque bottles and
similar-appearing contents and labeling.”
Kidd 2003
Methods Parallel-group RCT
Participants 519 participants with seasonal allergic conjunctivitis
Interventions Three treatment arms: ketotifen fumarate 0.025%; levocabastine 0.05%; placebo. Du-
ration of treatment 4 weeks
Outcomes Participant assessment (mean scores) of ocular itching (using a 5-point scale; 0 = none,
4 = severe) and watering (scale 0 = none, 3 = severe) within the first 4 days of treatment
Investigator assessment of signs (redness, eyelid swelling, chemosis) after treatment (using
a 5-point scale; 0 = none, 4 = severe)
Country Australia
Number randomised, gender (male:fe-
male)
519 participants randomised, 348 participants analysed. M:F 269:254
Age mean (SD), median, range Mean (SD): ketotifen 46.3 years (17.0); levocabastine 49.5 years (17.4); placebo 47.9
years (17.4)
Notes Not reported when study was conducted. Source of funding Novartis. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk RANCODE software (p.1207 - study design): “Eligible subjects
were randomised (RANCODE version 3.6) to one of the three
treatment groups...”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
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Kidd 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not intention-to-treat analysis, no reasons reported per protocol
deviations (large numbers). Number of participants randomised
(519) does not match the sum of male and female (523)
Selective reporting (reporting bias) Low risk Evidence was available of adequate outcome reporting.
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical packing (p.1207 - study design): “The packaging of all
trial medications was identical in appearance.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identical packing (p.1207 - study design): “The packaging of all
trial medications was identical in appearance.”
Lanier 2001
Methods Parallel-group RCT
Participants 94 participants with seasonal allergic conjunctivitis
Interventions Two treatment arms: olopatadine and oral loratadine; oral loratadine. Duration of treat-
ment 1 week
Outcomes Participants’ and physicians’ assessment of ocular signs and symptoms
Mean scores for ocular itching and redness using diaries and a 4-point scale
Time points: at baseline, day 3 and 7 after treatment
Country United States
Number randomised, gender (male:fe-
male)
94 participants randomised, 72 participants analysed. M:F 33:61
Age mean (SD), median, range Mean (range): olopatadine and oral loratadine 39 years (7-74); oral loratadine 37 years
(9-74)
Notes Study conducted fromMay toNovember 1998. Source of fundingAlconPharmaceutical.
Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
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Lanier 2001 (Continued)
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Exclusion of 22 participants after randomisation (p.644 - re-
sults): “Ten patients were not evaluable for efficacy because they
did not meet inclusion/exclusion criteria or had no follow up
examination... Twelve patients exited the study prematurely...”
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk (p.643 - study design): “Because there were no control eye drops,
patients were aware of their treatment groups, but clinicians
performing the evaluations in the clinic were not.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk (p.643 - study design): “Because there were no control eye drops,
patients were aware of their treatment groups, but clinicians
performing the evaluations in the clinic were not.”
Leino 1992
Methods Parallel-group RCT
Participants 195 participants with seasonal allergic conjunctivitis
Interventions Three treatment arms: nedocromil sodium 2%; sodium cromoglycate 2%; placebo. Du-
ration of treatment 4 weeks
Outcomes Overall assessment by participants and investigators using a 4-point scale
Country Finland
Number randomised, gender (male:fe-
male)
195 participants randomised, 185 participants analysed. M:F not stated
Age mean (SD), median, range Mean: nedocromil 20.8 years; sodium cromoglycate 19.3 years; placebo 19.7 years
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to conceal the allocation sequence was not
described
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Leino 1992 (Continued)
Allocation concealment (selection bias) Low risk (p.930 - material and methods): “After 1-2 weeks the patients
were issued their appropriate eye drops by randomized code
number...”
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal/exclusion of participants (p.931 - results): “Data
were returned from 195 patients, 10 of whomwithdrew without
taking test treatment and were excluded.”
“A further 12 patients (5 nedocromil sodium, 3 sodium cromo-
glycate and 4 placebo) withdrew from the study without com-
pleting the 4-week treatment period.”
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical drugs packaging (p.930 - medication): “All test drugs
were supplied in identical 10 ml plastic bottles.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identical drugs packaging (p.930 - medication): “All test drugs
were supplied in identical 10 ml plastic bottles.”
Lenhard 1997
Methods Parallel-group RCT
Participants 278 participants with seasonal allergic conjunctivitis or rhinoconjunctivitis
Interventions Three treatment arms: azelastine 0.025%; azelastine 0.05%; placebo. Duration of treat-
ment 14 days
Outcomes Investigator mean score of 3 symptoms (itching, tearing, and redness (secondary analysis)
) using a 4-point scale
Participants’ assessment of symptoms (itching primary variable) using diaries and a 4-
point scale
Time points: at baseline, at treatment day 7 and 14
Country France, Italy, Poland, and Slovenia
Number randomised, gender (male:fe-
male)
278 participants randomised, 226 participants analysed as per protocol. M:F 114:164
Age mean (SD), median, range Mean (SD) azelastine 0.025% 31.6 years (10.6); azelastine 0.05% 31.7 years (11.7);
placebo 33.9 years (11.9)
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Lenhard 1997 (Continued)
Notes Not reported when study was conducted. Source of funding ASTA Medica AG. Decla-
ration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of 278 recruited participants (p.24 - results): “226 patients com-
pleted the study as planned...” No reasons were given. (p.24 -
results): “Twenty-four of the 278 recruited patients discontin-
ued the study prematurely.”
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study did not describe details on masking of participants
on the intervention allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -The study did not describe details on masking of personnel/
investigators on the intervention allocations
McCabe 2012
Methods Parallel-group crossed-over RCT
Participants 30 participants recruited with allergic conjunctivitis
Interventions Two treatment arms: bepotastine besilate 1.5% ophthalmic solution; olopatadine hy-
drochloride 0.2%
Outcomes Participants’ assessment of ocular itching (using a 5-point Likert scale; 1 = lowest relief,
5 = highest relief ) at baseline and 2 other clinic visits but also using daily diary to assess
morning and evening ocular itch relief during 2 weeks of treatment
Country United States
Number randomised, gender (male:fe-
male)
30 participants randomised, M:F 10:20
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McCabe 2012 (Continued)
Age mean (SD), median, range Mean (SD) 49.8 (2.76), range 23-75
Notes Study conducted in September 2011. Source of funding not stated. No authors have
financial or proprietary interest in any material or method mentioned in this work
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list (p.1733 - materials and meth-
ods): “The enrolled patients were assigned sequen-
tially according to a computer-generated random-
ization list...”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence
was not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data reported, all the partici-
pants randomised were analysed
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were notmasked to treatment allocation
(p.1733 - material and methods): “ Each treatment
was provided in the packaging originally approved
by the Food and Drug Administration...”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigator was masked to treatment allocation (p.
1733 - material and methods): “...but the single in-
vestigator was masked as to which treatment the pa-
tient was currently using.”
Melamed 1994
Methods Parallel-group RCT
Participants 86 participants with seasonal allergic conjunctivitis
Interventions Two treatment arms: nedocromil sodium; placebo. Duration of treatment 8 weeks
Outcomes Participants’ assessment of symptoms -- sum score itching, burning, tearing, overall eye
condition
Clinicians’ assessment of ocular signs and symptoms (using a scale 0 = none, 4 = very
severe)
Time points: at baseline and peak pollen period during the 8 weeks of treatment
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Melamed 1994 (Continued)
Country United States
Number randomised, gender (male:fe-
male)
86 participants randomised, 85 participants analysed. M:F 49:36
Age mean (SD), median, range Mean (range) nedocromil sodium 33.1 years (13-60); placebo 31.1 years (13-57)
Notes Not reported when study was conducted. Source of funding: support in part by Fisons
Pharmaceuticals. Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked and identical package (p.58 - study design):
“The study was designed as a multicenter, randomized, double-
masked... Active and placebo drugs were packaged identically
and labeled in opaque polyethylene bottles...”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked and identical package (p. 58 - study design):
“The study was designed as a multicenter, randomized, double-
masked... Active and placebo drugs were packaged identically
and labeled in opaque polyethylene bottles...”
Melamed 2000
Methods Parallel-group RCT
Participants 189 participants with seasonal allergic conjunctivitis
Interventions Two treatment arms: nedocromil sodium 2%; vehicle. Duration of treatment 8 weeks
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Melamed 2000 (Continued)
Outcomes Participants’ assessment of various symptoms (composite score itching, burning, tearing,
overall eye condition) and diary cards (using a scale 0 = none, 4 = very severe) to assess
individual symptoms at treatment
Clinicians’ assessment of ocular signs and symptoms, and clinician and participant overall
opinions of treatment effectiveness at baseline and peak pollen season
Time scale: during the 8 weeks of treatment
Country United States
Number randomised, gender (male:fe-
male)
189 participants randomised. M:F 104:85
Age mean (SD), median, range Mean (range): nedocromil sodium 33.4 years (12-65); vehicle 31.0 years (13-67)
Notes Study conducted in August 1986. Source of funding: in part by Fisons Pharmaceuticals.
The authors did not have a financial interest in the drugs discussedwithin thismanuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up with similar percentage of participants lost to follow-up
in each arm, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.236 - study design): “The nine week studies
used a double-blind, placebo-controlled...”
Identical bottles (p.236 - study protocol): “At the end of the
baseline week, patients were randomised to receive either one
drop of nedocromil sodium 2% or vehicle solution b.i.d in each
eye, delivered from identical opaque bottles.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.236 - study design): “The nine week studies
used a double-blind, placebo-controlled...”
Identical bottles (p.236 - study protocol): “At the end of the
baseline week, patients were randomised to receive either one
drop of nedocromil sodium 2% or vehicle solution b.i.d in each
eye, delivered from identical opaque bottles.”
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Möller 1994
Methods Parallel-group RCT
Participants 149 participants with seasonal allergic conjunctivitis
Interventions Two treatment arms: nedocromil sodium; placebo. Duration of treatment 4 weeks
Outcomes Investigator’s and participants’ (or their parents’) assessment of severity of symptoms.
Mean score of itching, redness, soreness, grittiness, photophobia, and general eye con-
dition (using a 5-point scale; 0 = none, 4 = very severe)
Time points: during peak pollen in the 4 weeks of treatment
Country Sweden
Number randomised, gender (male:fe-
male)
149 participants randomised, 146 participants analysed. M:F 92:57
Age mean (SD), median, range Mean (range): nedocromil sodium 12 years (6-16); placebo 13 years (6-16)
Notes Not reported when study was conducted. Source of funding: Fisons Pharmaceuticals.
Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of predetermined randomised code (p.885 - patients and
methods): “Patients were then allocated, by a predetermined
randomised code... Trial supplies were coded at source, by com-
puter-generated numbers randomised in a balanced blocks of
four”
Allocation concealment (selection bias) Low risk Conceal allocation described (p.885 - patients and methods):
“Patients entering the trial were assigned to treatment numbers
in sequence. The codes were held in individual sealed envelopes
by the investigator, to be returned unopened after the trial.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.884 - summary): “This was a multicentre,
double-blind...”
(p.885 - patients and methods): “active or placebo eye drops
(both contained... in addition, the placebo eye drops contained
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Möller 1994 (Continued)
0.0005% rivoflavin as a yellow colorant to match the 2% ne-
docromil sodium content of the active eye drops).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.884 - summary): “This was a multicentre,
double-blind...”
(p.885 - patients and methods): “active or placebo eye drops
(both contained... in addition, the placebo eye drops contained
0.0005% rivoflavin as a yellow colorant to match the 2% ne-
docromil sodium content of the active eye drops).”
Nazarov 2003
Methods Parallel-group RCT
Participants 116 participants with moderate to severe perennial allergic conjunctivitis
Interventions Two treatment arms: azelastine 0.015 mg; placebo. Duration of treatment 6 weeks
Outcomes Participants’ and clinicians’ assessment of ocular symptoms (sum score itching and red-
ness, using a 4-point scale; 0 = none, 3 = severe)
Time points: at baseline and day 7, 21, and 42 of treatment
Country Germany
Number randomised, gender (male:fe-
male)
116 participants randomised and analysed. M:F 26:90
Age mean (SD), median, range Mean (range): azelastine 35.7 years (17-63); placebo 31.7 years (17-59)
Notes Study conducted from 19 December 1998 to 14 April 1999. Source of funding not
stated. Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
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Nazarov 2003 (Continued)
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.169 - patients, materials andmethods): “The
investigation was conducted as a double-blind, randomised...”
Both drugs with identical packaging (p.169 - treatment): “Both
azelastine eye drops and thematching vehicle containing placebo
were provided by ASTA Medica AG in identical packaging.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-masked (p.169 - patients, materials andmethods): “The
investigation was conducted as a double-blind, randomised...”
Both drugs with identical packaging (p.169 - treatment): “Both
azelastine eye drops and thematching vehicle containing placebo
were provided by ASTA Medica AG in identical packaging.”
Petzold 2002
Methods Parallel-group RCTs (3 RCTs reported together in abstract)
Participants Study 3034: 78 participants; Study 3062: 145 participants; Study 3021: 240 participants
with allergic conjunctivitis
Interventions Two treatment arms: azelastine 0.05%; placebo. Duration of treatment 14 or 28 days
Outcomes Investigators’ assessment of ocular symptoms (itching and redness) using a 4-point scale
(0 = none, 3 = severe)
Time scale: day 0, 3, and 14 of treatment
Country Europe
Number randomised, gender (male:fe-
male)
Study 3034: 78 participants (number of participants in each arm uncertain) randomised
Study 3062: 145 participants (number of participants in each arm uncertain)
Study 3021: 240 participants (number of participants in each arm uncertain). Gender
not stated (abstract)
Age mean (SD), median, range Age range 4-12 years
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Only abstract available
Allocation concealment (selection bias) Unclear risk Only abstract available
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Petzold 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only abstract available
Selective reporting (reporting bias) Unclear risk Only abstract available
Other bias Unclear risk Only abstract available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Only abstract available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Only abstract available
Sabbah 1998
Methods Parallel-group RCT
Participants 113 participants with seasonal allergic conjunctivitis/rhinoconjunctivitis
Interventions Three treatment arms: azelastine; levocabastine; placebo. Duration of treatment 14 days
Outcomes Participants’ (using diaries) and physicians’ assessments (sum scores) based on a decrease
of the average score > 3 units for three main eye symptoms (ocular itching, tearing, and
redness)
Time points: at baseline and day 3 and 14 of treatment
Country France
Number randomised, gender (male:fe-
male)
113 participants randomised, 107 participants analysed. M:F 75:38
Age mean (SD), median, range Mean (SD): azelastine 8.3 years (2.4); levocabastine 8.2 years (2.5); placebo 8.3 years (2.
3)
Notes Not reported when study was conducted. Source of funding Laboratoires ASTAMedica.
Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
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Sabbah 1998 (Continued)
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10% attrition, with similar numbers lost to follow-up between
arms
Selective reporting (reporting bias) Low risk Primary outcome result was reported according to protocol
Other bias Low risk No evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study did not describe details on masking of participants
on the intervention allocations. Masking was not done with
levocabastine due to labelling, but double-masked with other
interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study did not describe details on masking of personnel/
investigators on the intervention allocations. Masking was not




Participants 92 participants with allergic conjunctivitis
Interventions Two treatment arms: ketotifen fumarate 0.025%; olopatadine hydrochloride 0.1%. Du-
ration of treatment 2 weeks
Outcomes Assessment of ocular sign and symptoms (mean scores) for itching, tearing, hyperaemia,
photophobia (using a 4-point scale; 0 = none, 3 = severe)
Time points: at baseline and 2 weeks treatment period
Unclear if outcomes were measured by participants or clinicians, or both
Country Bangladesh
Number randomised, gender (male:fe-
male)
92 participants randomised, 83 participants analysed. M:F 36:47
Age mean (SD), median, range Mean (SD): ketotifen 28 years (12); olopatadine 28 years (11). Overall range 12-50 years
Notes Source of funding not stated. The authors have no relevant affiliations or financial
involvement with any organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
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Sarker 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation list (p.547 - treatment allocation and follow-up)
: “Patients who were found to be eligible according to selection
criteria were recruited in to one of the treatment groups accord-
ing to a stratified randomisation list based on age and sex.”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with less than 10% lost to fol-
low-up, and reasons were given
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.547 - treatment allocation and follow-up):
“Study medications were provided in identical containers so that
both patients and investigators remained blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study conducted from1 January to 31December 2007.Double-
masked (p.547 - treatment allocation and follow-up): “Study
medications were provided in identical containers so that both
patients and investigators remained blinded.”
Secchi 2000a
Methods Parallel-group RCT
Participants 42 paediatric participants with allergic conjunctivitis
Interventions Two treatment arms: emedastine 0.05%; levocabastine 0.05%. Duration of treatment
42 days
Outcomes Investigator assessment of ocular signs (using a scale 0-4) at days 3, 7, 14, 30, 42, and
overall progress
Participant assessment of ocular symptoms itching and redness (using a visual analogue
scale; 0 = none, 9 = severe)
Time points: at days 7, 14, 30, 42 of treatment
Country Italy
Number randomised, gender (male:fe-
male)
42 participants randomised, 38 participants analysed. Gender not stated
Age mean (SD), median, range Age range 4-6 years: 11 participants
Age range 7-16 years: 31 participants
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Secchi 2000a (Continued)
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were nearly fully reported, with 10% lost to follow-up,
reasons were given for one case only
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.42 - abstract, material and methods): “In a
randomised, double-masked... Subjects who met all inclusion
and exclusion criteria received masked study medication with
instructions to instill drops...”
Blinding of outcome assessment (detection
bias)
All outcomes




Participants 222 participants (including 42 paediatric) with seasonal allergic conjunctivitis
Interventions Two treatment arms: emedastine 0.05%; levocabastine 0.05%. Duration of treatment
42 days
Outcomes Investigator assessment of ocular signs (using a scale 0-4) at days 3, 7, 14, 30, 42 Partici-
pant assessment of ocular symptoms (using a visual analogue scale; 0 = none, 9 = severe)
at days 7, 14, 30, 42
Country Italy and United States
Number randomised, gender (male:fe-
male)
202 participants randomised. M:F 107:114
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Secchi 2000b (Continued)
Age mean (SD), median, range Average age (range): 30 years (4-76)
Notes Not reported when study was conducted. Source of funding not stated. Declaration of
interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere nearly fully reported for each intervention group, with
less than 20% lost to follow-up (Figure 1 of the trial report). A
similar percentage of participants was lost to follow-up in each
arm
Selective reporting (reporting bias) Unclear risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-masked (p.49 - material and methods): “In a random-
ized, double-masked...”
Blinding of outcome assessment (detection
bias)
All outcomes




Participants 357 participants with perennial or seasonal allergic conjunctivitis
Interventions Two treatment arms: mequitazine; levocabastine. Duration of treatment 4 weeks
Outcomes Investigators’ assessment of symptoms at day 7, 14, and 28 Participants’ assessment of
symptoms (diary cards)
Country Not stated
Number randomised, gender (male:fe-
male)
357 participants randomised
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Trinquand 1999 (Continued)
Age mean (SD), median, range Not stated
Notes Not reported when study was conducted. Full-text paper not available, only abstract,
therefore insufficient information to assess risk of bias. Source of funding and declaration
of interest by the authors were not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Only abstract available
Allocation concealment (selection bias) Unclear risk Only abstract available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only abstract available
Selective reporting (reporting bias) Unclear risk Only abstract available
Other bias Unclear risk Only abstract available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Only abstract available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Only abstract available
Varguez-Rodriguez 2009
Methods Parallel-group RCT
Participants 40 participants (naive-treatment) with seasonal allergic conjunctivitis
Interventions Two treatment arms: olopatadine 0.1%; ketotifen 0.025%. Duration of treatment 4
weeks
Outcomes Assessment of ocular symptoms: itching, watering, burning (range 0-3; 0 = none, 3 =
severe) and signs: redness, chemosis (absent, present)
Unclear if outcomes were measured by participants or clinicians, or both
Country Mexico
Number randomised, gender (male:fe-
male)
40 participants randomised. M:F 23:17
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Varguez-Rodriguez 2009 (Continued)
Age mean (SD), median, range Mean (SD): olopatadine 19.7 years (6.6); ketotifen 21.05 years (8.3)
Notes Source of funding not stated. Declaration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data reported, all the participants ran-
domised were analysed
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants (p.401 - methods): “All the bottles had
the same appearance and the patient did not know the treatment
received.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking of investigators (p.401 - methods): “All the bottles had




Participants 222 participants with seasonal allergic conjunctivitis
Interventions Two treatment arms: levocabastine; emedastine. Duration of treatment 6 weeks
Outcomes Participants’ assessment of itching and redness using diaries and visual analogue scale (0
= none; 9 = severe)
Physician assessment of itching, redness
Time points: day 0-14 and day 30-42 of treatment
Country Europe, South Africa, and Australia
Number randomised, gender (male:fe-
male)
222 participants randomised, 202 participants analysed. Gender not stated
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Verin 2001 (Continued)
Age mean (SD), median, range Mean (range) 30 years (4-76)
Notes Not reported when study was conducted. Source of funding Alcon Research Ltd. Dec-
laration of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the allocation sequence was not
described
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not intention-to-treat analysis
Selective reporting (reporting bias) Low risk Evidence was available of proper outcome reporting
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical containers (p.692 -methods): “Studymedicationswere
provided in identical containers so that both patients and inves-
tigators remained masked.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identical containers (p.692 -methods): “Studymedicationswere




Participants 69 participants with acute allergic conjunctivitis
Interventions Two treatment arms: antazoline 0.05% and tetryzoline 0.04%; levocabastine 0.05%.
Duration of treatment 2 weeks
Outcomes The total symptom score (Figure 1 of the trial report) of eight symptoms (each scored
0 = none; 3 = worst symptom). Four subjective and four objective symptoms; unclear
which symptoms were assessed by participants or clinicians
Country Germany
Number randomised, gender (male:fe-
male)
69 participants randomised. M:F 35:34
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Wertheimer 1997 (Continued)
Age mean (SD), median, range Mean (SD): antazoline and tetryzoline 42.4 (15.4); levocabastine 43.1 (14.9)
Notes Study conducted fromMarch to August 1995. Source of funding not stated. Declaration
of interest by the authors was not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generation (p.94): “The randomisation
schedule, created at random in blocks of four, assigned patients
to the medications and application instructions listed in Table
2”
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation sequence was not
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts were mentioned
Selective reporting (reporting bias) High risk Only P values that were statistically significant were reported (p.
95, paragraph 3). No results were reported for outcomes that
were not statistically significant (p.94, paragraph 8). Numerical
results were not reported in the text for any outcomes except for
the numbers with blurred vision (p.95, paragraph 4)
Other bias Low risk No apparent evidence of other risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk (p. 94, paragraph 3): “After 30 minutes the eyes were studied
again, without the doctor knowing which drops were adminis-
tered. The medication and the double-masked application in-
structions, which prevented early identification of the medica-
tion, were handed over to the patient at the end of the visit”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Masked at 30-minute assessment, later assessments were not
masked to participants, as treatments had different dose frequen-
cies (2 per day versus 4 per day). Assessmentmasked to clinicians
unclear
RCT: randomised controlled trial
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abelson 2003 Using conjunctival allergen challenge test
Abelson 2004 Using conjunctival allergen challenge test
Artal 2000 Unit of randomisation: eye (participants received different treatments on each eye)
Borazan 2009 Unit of randomisation: eye (participants received different treatments on each eye)
Garay 2001 Non-randomised controlled trial
Higuchi 1979 Non-randomised controlled trial
Kamis 2006 Unit of randomisation: eye (participants received different treatments on each eye)
Leino 1994 Comparing different concentrations and dosage of the same active drug
Leonardi 2004 Non-randomised controlled trial
Longo 1979 Non-randomised controlled trial
Merayo 2003 Non-randomised controlled trial
Möller 1990 Non-randomised controlled trial
Napoli 2005 Non-randomised controlled trial
Pinto 2001 Cost-effectiveness study (original study Verin 2001)
Scadding 1999 Non-randomised controlled trial
Scoper 2007 Non-randomised controlled trial
Torkildsen 2008 Unit of randomisation: eye (participants received different treatments in each eye)
Characteristics of studies awaiting assessment [ordered by study ID]
Dharmistha 2013
Methods No details, unclear if it is a RCT
Participants Allergic conjunctivitis
Interventions Topical olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.025%
67Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis (Review)





Methods No details, unclear if it is a RCT
Participants Children with allergic conjunctivitis
Interventions Azelastine
Outcomes No details




Interventions Olopatadine hydrochloride 0.2% ophthalmic solution once daily versus sodium cromoglycate 2% ophthalmic solu-
tion 4 times a day
Outcomes Efficacy and tolerability. No further details
Notes Reported at the 46th Annual Conference of the Indian Pharmacological Society, IPSCON Bangalore India, 2013
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Olopatadine versus ketotifen




participants Statistical method Effect size
1 Itching at 14 days 4 182 Mean Difference (IV, Random, 95% CI) -0.32 [-0.59, -0.06]
2 Tearing at 14 days 3 142 Mean Difference (IV, Random, 95% CI) -0.06 [-0.35, 0.22]
Analysis 1.1. Comparison 1 Olopatadine versus ketotifen, Outcome 1 Itching at 14 days.
Review: Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis
Comparison: 1 Olopatadine versus ketotifen
Outcome: 1 Itching at 14 days





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Avunduk 2005 13 0.76 (0.1) 12 1.08 (0.2) 28.6 % -0.32 [ -0.45, -0.19 ]
Ho¨ffling-Lima 2001 16 0.5 (0.36) 18 0.56 (0.4) 23.7 % -0.06 [ -0.31, 0.20 ]
Sarker 2011 40 0.33 (0.608) 43 1.09 (0.527) 24.2 % -0.76 [ -1.01, -0.51 ]
Varguez-Rodriguez 2009 20 1.15 (0.37) 20 1.3 (0.47) 23.5 % -0.15 [ -0.41, 0.11 ]
Total (95% CI) 89 93 100.0 % -0.32 [ -0.59, -0.06 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 18.03, df = 3 (P = 0.00043); I2 =83%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours olopatadine Favours ketotifen
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Analysis 1.2. Comparison 1 Olopatadine versus ketotifen, Outcome 2 Tearing at 14 days.
Review: Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis
Comparison: 1 Olopatadine versus ketotifen
Outcome: 2 Tearing at 14 days





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Avunduk 2005 13 0.3 (0.1) 12 0.17 (0.1) 36.4 % 0.13 [ 0.05, 0.21 ]
Ho¨ffling-Lima 2001 16 0.125 (0.129) 18 0.11 (0.38) 32.2 % 0.01 [ -0.17, 0.20 ]
Sarker 2011 40 0.03 (0.158) 43 0.4 (0.66) 31.4 % -0.37 [ -0.57, -0.17 ]
Total (95% CI) 69 73 100.0 % -0.06 [ -0.35, 0.22 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 20.48, df = 2 (P = 0.00004); I2 =90%
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours olopatadine Favours ketotifen
A D D I T I O N A L T A B L E S
Table 1. Serious adverse events and withdrawals
Study Serious adverse events Number withdrawn due to side
effects
Treatment arm from which
withdrawn
Avunduk 2005 No serious adverse events re-
ported
No participants recorded to have
withdrawn
N/A
Azevedo 1991 No serious adverse events re-
ported
1 participant withdrawn 1 from placebo group
Canonica 2003 No serious adverse events re-
ported
2 participants withdrawn 1 from azelastine and 1 from
placebo
Carr 2013 1 serious adverse event reported
unrelated to the treatment
11 participants withdrawn 4 from bepotastine besilate and 7
from placebo
Davies 1993 No serious adverse events re-
ported
5 participants withdrawn 2 from levocabastine group and 3
from placebo
Fujishima 2008 No serious adverse events re-
ported
No participants recorded to have
withdrawn
N/A
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Table 1. Serious adverse events and withdrawals (Continued)





Graue 1994 No serious adverse events re-
ported
2 participants withdrawn 1 from levocabastine and 1 from
placebo
Hechanova 1984 No serious adverse events re-
ported
12 participants withdrawn 2 from cromoglycate group and
10 from placebo group
Höffling-Lima 2001 No serious adverse events re-
ported
No participants recorded to have
withdrawn
N/A
James 2003 No serious adverse events re-
ported
4 participants withdrawn due to
side effects
1 from azelastine, 2 from cromo-
glycate, and 1 from placebo
Katelaris 2002 No serious adverse events re-
ported
2 participants withdrawn 1 from olopatadine group, 1 from
cromolyn group
Kidd 2003 4 serious adverse events: 1) per-
sistent photophobia and 2) con-
junctivitis with corneal ulcer
38 discontinued due to side ef-
fects
8 from ketotifen, 15 from levo-
cabastine, 15 from placebo
Lanier 2001 No serious adverse events re-
ported
No participants recorded to have
withdrawn
N/A
Leino 1992 No serious adverse events re-
ported
4 participants withdrawn 3 from nedocromil and 1 from
cromoglycate
Lenhard 1997 No serious adverse events re-
ported
4 participants withdrawn 2 from azelastine group and 2
from placebo group
McCabe 2012 No serious adverse events re-
ported
No participants recorded to have
withdrawn
N/A
Melamed 1994 No serious adverse events re-
ported
No participants recorded to have
withdrawn due to side effects
N/A
Melamed 2000 No serious adverse events re-
ported
No participants recorded to have
withdrawn due to side effects
N/A
Moller 1994 No serious adverse events re-
ported
No participants recorded to have
withdrawn due to side effects
N/A
Nazarov 2003 No serious adverse events re-
ported
1 participant withdrawn due to
side effects
1 participant from azelastine
group
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Table 1. Serious adverse events and withdrawals (Continued)
Petzold a,b,c 2002 No serious adverse events re-
ported
No participants recorded to have
withdrawn due to side effects
N/A
Sabbah 1998 No serious adverse events re-
ported
1 participant withdrawn 1 participant from azelastine
group
Sarker 2011 No serious adverse events re-
ported
Nomention of participants with-
drawing due to side effects
N/A
Secchi a 2000 No serious adverse events re-
ported
1 participant discontinued due to
side effects
1 participant from emedastine
Secchi b 2000 No serious adverse events re-
ported
Nomention of participants with-
drawing due to side effects
N/A
Trinquand 1999 No serious adverse events re-
ported
Nomention of participants with-
drawing due to side effects
N/A
Varguez-Rodriguez 2009 No serious adverse events re-
ported
No participants recorded to have
withdrawn
N/A
Verin 2001 No serious adverse events re-
ported
3 participants withdrawn 3 participants from emedastine
group
Wertheimer 1997 No serious adverse events re-
ported
No participants recorded to have
withdrawn due to side effects
N/A
N/A: not applicable
A P P E N D I C E S
Appendix 1. Listed medications and mechanism of action
Antazoline - pure antihistamine
Azelastine - antihistamine + mast cell stabiliser
Bepotastine besilate - antihistamine + mast cell stabiliser
Carebastine - developing drug - pure antihistamine
Levocabastine - pure antihistamine
Emedastine - pure antihistamine
Ketotifen - antihistamine + mast cell stabiliser
Olopatadine - antihistamine + mast cell stabiliser
Epinastine - antihistamine + mast cell stabiliser
Sodium chromoglycate - antihistamine + mast cell stabiliser
Nedocromil sodium - antihistamine + mast cell stabiliser
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Lodoxamide - antihistamine + mast cell stabiliser
Tranilast - developing drug - antihistamine + mast cell stabiliser
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Conjunctivitis, Allergic
#2 conjunctivitis
#3 pollen near/3 allerg*
#4 hayfever
#5 hay near/2 fever
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Histamine H1 Antagonists
#8 antihistamin* or anti-histamin*
#9 antazolin*
#10 azelastin*








#19 MeSH descriptor Cromolyn Sodium
#20 sodium chromoglycate




#25 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR
#22 OR #23 OR #24)
#26 (#6 AND #25)
Appendix 3. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. conjunctivitis, allergic/
14. conjunctivitis.tw.
15. (pollen adj3 allerg$).tw.
16. hayfever.tw.
17. (hay adj2 fever).tw.
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18. or/13-17
19. exp histamine h1 antagonists/
20. (antihistamin$ or anti-histamin$).tw.
21. antazolin$.tw.
22. azelastin$.tw.















38. 18 and 37
39. 12 and 38
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 4. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
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27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp allergic conjunctivitis/
34. conjunctivitis.tw.
35. (pollen adj3 allerg$).tw.
36. hayfever.tw.
37. (hay adj2 fever).tw.
38. or/33-37
39. histamine H1 receptor antagonist/



























67. 38 and 66
68. 32 and 67
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Appendix 5. metaRegister of Controlled Trials search strategy
allergic conjunctivitis and antihistamine
Appendix 6. ClinicalTrials.gov search strategy
allergic conjunctivitis AND antihistamine
Appendix 7. ICTRP search strategy
allergic conjunctivitis AND antihistamine
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N O T E S
The current protocol is an update of a published protocol by Purohit G, Jayabalan P, Ratnasingham K, Patter A. Topical antihistamines
for seasonal and perennial allergic conjunctivitis. Cochrane Database of Systematic Reviews 2006, Issue 1. The ’Background’ and
’Objectives’ sections of the protocol have been updated, and the ’Methods’ section has been rewritten in line with updated Cochrane
methodology. The protocol has also been peer reviewed again.
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